

CHIRAL QUEST INC
Form 424B3
April 28, 2004

Filed pursuant to Rule 424(b)(3)

File No. 333-113980

OFFERING PROSPECTUS

Chiral Quest, Inc.

7,723,041 Shares

Common Stock

The selling shareholders identified on pages 35-38 of this prospectus are offering on a resale basis a total of 7,723,041 shares of our common stock, including 2,896,135 shares issuable upon the exercise of outstanding warrants. We will not receive any proceeds from the sale of these shares by the selling shareholders.

Our common stock is quoted on the Over-the-Counter Bulletin Board under the symbol CQST. On April, 26, 2004, the last sale price for our common stock as reported on the OTC Bulletin Board was \$ 1.50 .

**The securities offered by this prospectus involve a high degree of risk.
See Risk Factors beginning on page 5.**

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined that this prospectus is truthful or complete. A representation to the contrary is a criminal offense.

Edgar Filing: CHIRAL QUEST INC - Form 424B3

The date of this Prospectus is April 26, 2004.

Table of Contents

	Page
Prospectus Summary	3
Risk Factors	5
Note Regarding Forward Looking Statements	13
Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Our Company	21
Management	28
Principal Shareholders	33
Certain Transactions and Relationships	34
Market for Common Equity and Related Shareholder Matters	34
Use of Proceeds	35
Selling Shareholders	35
Plan of Distribution	39
Description of Capital Stock	41
Disclosure Of Commission Position On Indemnification For Securities Act Liabilities	42
About This Prospectus	42
Where You Can Find More Information	43
Validity of Common Stock	43
Experts	43
Changes in Certifying Accountant	43
Financial Statements	F-1

PROSPECTUS SUMMARY

This summary provides a brief overview of the key aspects of this offering. Because it is only a summary, it does not contain all of the detailed information contained elsewhere in this prospectus or in the documents included as exhibits to the registration statement that contains this prospectus. Accordingly, you are urged to carefully review this prospectus in its entirety.

Our Company

We are a research-driven company engaged in the commercial development of asymmetric catalysis products and technology. We have the rights to certain chemical compounds known as chiral ligands which, with the introduction of a metal, serve as catalysts in facilitating the production of chiral molecules in such a manner that there is a preferential manufacture of the desired molecule versus the unwanted mirror-image molecule. We provide pharmaceutical and fine chemical manufacturers and other prospective customers with broad access to our technologies for testing purposes at a low upfront cost, coupled with the opportunity to gain exclusive access to such technologies for specific applications for fees, royalties and certain manufacturing and development rights. We also plan to provide specialized services to pharmaceutical, biotechnology and fine chemical companies relating to the development of chiral manufacturing processes for their products. We believe that our ligands may also be useful in producing fine chemicals other than pharmaceuticals. Chiral molecules are used in flavors, fragrances, agrochemicals, animal health, food and feed additives (including vitamins) and nutraceuticals.

Our proprietary technology was developed by Dr. Xumu Zhang, Ph.D., a professor at Pennsylvania State University (Penn State), and is owned by the Penn State Research Foundation (the PSRF), the technology development arm of Penn State. In October 2000, we obtained from PSRF an exclusive, worldwide license to certain patents based on Dr. Zhang's research relating to asymmetrical catalysis. This license gives us the right to, among other things, sub-license technology rights on a non-exclusive basis to customers, or sell molecule groups, known as ligands, to pharmaceutical and fine chemical company customers for both research and commercial applications.

Chiral Quest, Inc., a Minnesota corporation, resulted from the reverse merger of Chiral Quest, LLC, a Pennsylvania limited liability company that commenced operations in October 2000, and Surg II, Inc., a Minnesota corporation, on February 18, 2003. Our executive offices are located at Princeton Corporate Plaza, 7 Deer Park Drive, Suite E, Monmouth Junction, New Jersey 08852 and our telephone number is (732) 274-0399. Our Internet site is www.chiralquest.com.

Recent Developments

Management Changes

On April 16, 2004, we announced that Alan D. Roth, Ph.D., our President, Chief Executive Officer and Chief Financial Officer, had resigned from those positions. Dr. Roth also resigned from our board of directors. Dr. Roth will continue to be employed by us until June 30, 2004, or such earlier date as Dr. Roth determines, in order to assist us as we transition to a new chief executive officer. During this transition period, Dr. Roth will continue to receive his annualized base salary of \$240,000. In connection with his separation, we have agreed to pay Dr. Roth a severance fee of \$375,000, less the amount of salary paid to him during the remaining period of his employment. Dr. Roth has also agreed to terminate all of his outstanding stock options.

We have begun searching for Dr. Roth's replacement. Ronald Brandt has been appointed to serve as interim chief executive officer until we have found Dr. Roth's successor. Mr. Brandt has been our vice president of business development since joining us in October 2003. Additionally, Yaping Hong, Ph.D. has been appointed to serve as our interim chief operating officer and Brian Lenz has been appointed interim chief financial officer. Dr. Hong has been with our company since June 2003 serving as our Director of Process Research and Development. Brian Lenz has been our controller since October 2003 and our secretary since January 2004. In connection with their appointments, Mr. Brandt and Mr. Lenz each were granted an option under our 2003 Stock Option Plan to purchase 25,000 shares of our common stock at a price of \$1.40 per share. Dr. Hong also received an option to purchase 50,000 shares at a price of \$1.40 per share. All of the options granted vest in three equal annual installments beginning April 2005.

Private Placement

In February 2004, we completed a private placement of 4,826,906 shares of our common stock at a per share price of \$1.50. Each investor in the offering was also entitled to a five-year warrant to purchase one-half of the number of common shares purchased by the investor at a price of \$1.65 per share. Accordingly, in connection with the private placement, we issued warrants to purchase an aggregate of 2,413,444 shares of common stock. After deducting commissions and other expenses relating to the private placement, we received aggregate net proceeds of approximately \$6.67 million. We also issued to the placement agents engaged in connection with the private placement 5-year warrants to

Edgar Filing: CHIRAL QUEST INC - Form 424B3

purchase an aggregate of 482,691 shares of our common stock at a price of \$1.65 per share.

Risk Factors

For a discussion of some of the risks you should consider before purchasing shares of our common stock, you are urged to carefully review and consider the section entitled "Risk Factors" beginning on page 5 of this prospectus.

The Offering

The selling shareholders identified on pages 35-38 of this prospectus are offering on a resale basis a total of 7,723,041 shares of the following shares of our common stock:

- 4,826,906 shares of our outstanding common stock issued in connection with our February 2004 private placement;
- 2,413,444 shares of our common stock issuable at a price of \$1.65 per share upon the exercise of warrants issued to the investors in our February 2004 private placement; and
- 482,691 shares of our common stock issuable at a price of \$1.65 per share upon the exercise of warrants issued to the placement agents in connection with our February 2004 private placement.

Common stock offered	7,723,041 shares
Common stock outstanding before the offering ⁽¹⁾	17,827,924 shares
Common stock outstanding after the offering ⁽²⁾	20,724,059 shares
Common Stock OTC Bulletin Board symbol	CQST.OB

- (1) Based on the number of shares outstanding as of April 26, 2004, not including 2,076,347 shares issuable upon exercise of various warrants and options to purchase common stock.
- (2) Assumes the issuance of all shares offered hereby that are issuable upon exercise of warrants.

RISK FACTORS

An investment in our common stock is very risky. You may lose the entire amount of your investment. Prior to making an investment decision, you should carefully review this entire prospectus and consider the following risk factors:

Risks Related to Our Securities

Trading of our common stock is limited.

Trading of our common stock is conducted on the National Association of Securities Dealers Over-the-Counter Bulletin Board, or OTC Bulletin Board. This adversely affects the liquidity of our common stock, not only in terms of the number of shares that can be bought and sold at a given price, but also through delays in the timing of transactions and reduction in security analysts' and the media's coverage of us. This may result in lower prices for our common stock than might otherwise be obtained and could also result in a larger spread between the bid and asked prices for our common stock.

Because it is a penny stock, it will be more difficult for you to sell shares of our common stock.

In addition, because our common stock trades on the OTC Bulletin Board and at a price lower than \$5.00, it is considered a penny stock. Broker-dealers who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure document prepared by the SEC. This document provides information about penny stocks and the nature and level of risks involved in investing in the penny-stock market. A broker must also give a purchaser, orally or in writing, bid and offer quotations and information regarding broker and salesperson compensation, make a written determination that the penny stock is a suitable investment for the purchaser, and obtain the purchaser's written agreement to the purchase. The penny stock rules may make it difficult for you to sell your shares of our stock. Because of the rules, there is less trading in penny stocks. Also, many brokers choose not to participate in penny-stock transactions. Accordingly, you may not always be able to resell shares of our common stock publicly at times and prices that you feel are appropriate.

A significant number of shares of our common stock are or will become available for sale and their sale could depress the price of our common stock.

A substantial number of shares of our common stock are being offered by this prospectus. We may also issue additional shares in connection with our business and may grant additional stock options to our employees, officers, directors and consultants or warrants to third parties. Sales of a substantial number of shares of our common stock in the public market after this offering could adversely affect the market price for our common stock and make it more difficult for you to sell our shares at times and prices that you feel are appropriate.

Our stock price is, and we expect it to remain, volatile, which could limit investors' ability to sell stock at a profit.

The volatile price of our stock makes it difficult for investors to predict the value of their investment, to sell shares at a profit at any given time, or to plan purchases and sales in advance. A variety of factors may affect the market price of our common stock. These include, but are not limited to:

- announcements of technological innovations or new commercial products by our competitors or us;
- developments concerning proprietary rights, including patents;
- regulatory developments in the United States and foreign countries;
- economic or other crises and other external factors;
- period-to-period fluctuations in our revenues and other results of operations;
- changes in financial estimates by securities analysts; and
- sales of our common stock.

We will not be able to control many of these factors, and we believe that period-to-period comparisons of our financial results will not necessarily be indicative of our future performance.

In addition, the stock market in general, and the market for biotechnology companies in particular, has experienced extreme price and volume fluctuations that may have been unrelated or disproportionate to the operating performance of individual companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance.

We do not expect to pay dividends.

We have never paid dividends on our capital stock and do not anticipate paying any dividends for the foreseeable future. Accordingly, the only time that you will realize a return, if any, on your investment in our common stock is when you sell your shares.

Risks Relating to our Business

Our future success is highly dependent on the continued availability of Dr. Xumu Zhang and other key employees and consultants.

In connection with the continued development of our products and services, we are substantially dependent upon on the continued service of its existing research personnel, including in particular, Xumu Zhang, Ph.D. Dr. Zhang, an associate professor at Penn State, who serves as our Chief Technology Officer and provides essential services to us pursuant to a consulting agreement. Although we maintain a \$2 million key-man insurance policy with respect to Dr. Zhang and he has entered into a non-compete agreement with us, the loss of his services would have a material adverse effect on our business. In addition to Dr. Zhang, we employ other research scientists who are also critical to our success. Although these research scientists have entered into confidentiality agreements, most have not entered into noncompete agreements with us. The loss of one or more of our research personnel could prevent or delay the ongoing development of our products and services, which would materially and adversely affect our business.

We have no meaningful operating history on which to evaluate our business or prospects.

We commenced operations in October 2000 and, therefore, have only a limited operating history on which you can base an evaluation of our business and prospects. Accordingly, our business prospects must be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by companies in their early stages of development, particularly companies in new and rapidly evolving markets, such as the fine chemical, pharmaceutical and biotechnology markets.

A small group of persons is able to exert significant control over our company.

Our current officers and directors beneficially own or control approximately 21% of our common stock. Individually and in the aggregate, these persons will have significant influence over the management of our business, the election of directors and all matters requiring shareholder approval. In particular, this concentration of ownership may have the effect of facilitating, delaying, deferring or preventing a potential acquisition of our company and may adversely affect the market price of our common stock. Additionally, three members of our Board of Directors are employees of Paramount BioCapital, Inc., or one of its affiliates. Dr. Lindsay A. Rosenwald is the chairman and sole owner of Paramount BioCapital, Inc. and such affiliates. Dr. Rosenwald beneficially owns 3.6% of our outstanding common stock, and several trusts for the benefit of Dr. Rosenwald and his family beneficially own 10.7% of our outstanding common stock. Although Dr. Rosenwald does not have the legal authority to exercise voting power or investment discretion over the shares held by those trusts, he nevertheless may have the ability to exert significant influence over the Company.

Our management anticipates incurring losses for the foreseeable future.

For the year ending December 31, 2003, we had a net loss of \$2,018,400 and since our inception in October 2000 through December 31, 2003, we have incurred an aggregate net loss of \$3,411,205. As of December 31, 2003, we had total assets of \$1,585,857, of which \$659,117 was cash or cash equivalents. We expect operating losses to continue for the foreseeable future and there can be no assurance that we will ever be able to operate profitably.

We will require additional financing in order to complete the development of our products and services and otherwise develop our business operations. Such financing may not be available on acceptable terms, if at all.

Following the completion of our February 2004 private placement, we anticipate that our current capital will be adequate to fund our operations at least through December 31, 2004. However, changes may occur that would consume available capital resources before that time. Our combined capital requirements will depend on numerous factors, including competing technological and market developments; changes in our existing collaborative relationships; the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights and the outcome of any potentially related litigation or other dispute; the purchase of additional capital equipment; acquisition of technologies; and the development and regulatory approval progress of our customers' product candidates into which our technology will be incorporated.

Additional capital that may be needed by us in the future may not be available on reasonable terms, or at all. If adequate financing is not available, we may be required to terminate or significantly curtail our operations, or enter into arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies, or potential markets that we would not otherwise relinquish.

Our operating results will fluctuate, making it difficult to predict our results of operations in any future period.

As we develop our business, we expect our revenues and operating results to vary significantly from quarter-to-quarter. As a result, quarter-to-quarter comparisons of our revenues and operating results may not be meaningful. In addition, due to the fact that we have little or no significant operating history with our new technology, we cannot predict our future revenues or results of operations accurately. Our current and future expense levels are based largely on our planned expenditures and estimates of future revenues. Accordingly, we may be unable to adjust spending in a timely manner to compensate for any unexpected revenue shortfall, and any significant shortfall in revenues relative to our planned expenditures could have an immediate adverse effect on our business and results of operations.

We may be unable to develop successful customer relationships.

We intend to establish relationships with various types of customers and partners, such as pharmaceutical and fine chemical manufacturers. Each of these relationships will involve negotiation of terms and fees. We cannot be certain that we will be able to negotiate profitable relationships or that we can successfully fulfill our obligations under development agreements that will allow us to continue these relationships.

Our license agreement with Penn State Research Foundation may be terminated if we do not achieve certain milestones.

Our business is based on technically complex products and services. We do not directly own our proprietary technology, but rather we have the exclusive, worldwide right to use it pursuant to a license agreement with the Penn State Research Foundation. Currently, our commercial success depends entirely on this licensed technology. Pursuant to the license agreement, we are required to use our best efforts to achieve gross revenue (as defined in the license agreement) of at least \$250,000 in 2004, at least \$350,000 in 2005 and at least \$500,000 in 2006. In the event we fail to achieve these milestones, or otherwise materially breach the license agreement, the Penn State Research Foundation may have the right, but not the obligation, to terminate the license. Unless we subsequently develop our own technology independent of the Penn State Research Foundation, termination of this license would preclude us from implementing our business plan.

We may rely heavily on third parties to formulate and manufacture our products.

We currently lack the resources to formulate or manufacture the overwhelming majority of our own products on a commercial scale. If any of our customers require our ligands in commercial quantities in the near term, we may have to rely on one or more third-party contractors to manufacture the ligands to satisfy the needs of such customers. Reliance on one or more third-party manufacturers exposes us to certain risks, including the following:

- We may be unable to replace manufacturers on commercially reasonable terms or at all because the number of potential manufacturers is limited, and the United States Food and Drug Administration (FDA), or such similar regulatory authorities, may have to approve any replacement contractor;
- Third-party manufacturers might be unable to formulate and manufacture our ligands in the volume and of the quality required to meet customers' clinical and commercial needs;
- Our existing and future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our customers to complete their clinical trials or to successfully produce, store and distribute our products;
- Drug manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state agencies to ensure strict compliance with good manufacturing practice and other government regulations and corresponding foreign standards, which we would be unable to control; and
- If any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to the innovation.

Each of these risks could delay the clinical trials conducted by our customers, approvals required by regulatory authorities, and the commercialization of some of our customers' product candidates. These risks could also result in higher costs to the customer or could deprive us of potential product revenues.

We will need to create and grow our scientific, sales and support operations.

We will need to create and substantially grow our direct and indirect sales operations, both domestically and internationally, in order to create and increase market awareness and sales of our products and services. The sale of our products and services will require the engagement of sophisticated and highly knowledgeable sales personnel. Similarly, the anticipated complexity of our products and services and the difficulty of customizing them will require us to hire research and development personnel and support personnel, highly trained in chiral chemistry and chemical engineering. Competition among our company and others to retain qualified sales personnel, chemists and chemical engineers is intense due to the limited number of available qualified candidates for such positions. Many of our competitors are in a financial position to offer potential employees greater compensation and benefits than those which may be offered by us. Failure to recruit and retain such persons will have a material adverse effect on our business operations.

Our future success is dependent on the management of our potential growth.

Our future success depends upon our ability to grow our business. Such growth, if it occurs, will require us to establish management and operating systems, hire additional technical support and sales personnel, and establish and maintain our own independent office, research and production facilities. Failure to manage that growth efficiently could have a material adverse effect on our business.

We currently have no capabilities and no experience in manufacturing our products on a commercial scale.

We do not currently have the experience or ability to directly manufacture or market most chemical or pharmaceutical products in commercial quantities that may be developed under our collaborative arrangements. Even though, with the opening of our Princeton, New Jersey facility, we have the capacity to develop certain of our products on a commercial scale, we most likely will not be able to produce all of our ligands on a commercial scale at the Princeton facility. In addition, we have not yet developed a cost effective and efficient commercial manufacturing process for some of our ligands, and may never be able to do so. To the extent we are unable to produce, directly or indirectly, our ligands in quantities required for commercial use, we will not realize any benefits from our technology. Further, in the event we decide to establish a manufacturing facility in the future, we may require substantial additional funds, and will be required to hire and train a significant number of additional personnel, and, in certain circumstances, may need to comply with the extensive FDA good manufacturing practice regulations applicable to such a facility.

Risks Relating to Our Industry

We face intense competition.

We compete directly with the in-house research departments of fine chemical, pharmaceutical and biotechnology companies, as well as contract research companies, and research and academic institutions. Many of our competitors have greater financial and other resources than us. As new companies enter the market and as more advanced technologies become available, we expect to face increased competition. In the future, any one of our competitors may develop technological advances that render obsolete the products or services that we provide or may provide in the future. While we plan to develop new and better technologies, which will give us competitive advantages, our competitors plan to do the same. We may not be able to develop the technologies we need to successfully compete in the future, and our competitors may be able to develop such technologies before we do. Consequently, we may not be able to successfully compete in the future.

The fine chemical, pharmaceutical and biotechnology industries involve rapidly changing technologies.

Rapid technological change and uncertainty due to new and emerging technologies characterize the drug and fine chemical development industries. We may not be able to develop, integrate and market, on a timely basis, the new and enhanced products and services necessary to keep pace with competitors. Failure to anticipate or to respond to changing technologies, or significant delays in product development or introduction, could cause our customers to delay or decide against purchases of our products or services.

Since many of our customers and potential customers are pharmaceutical and biotechnology companies, we are and will be subject to risks, uncertainties and trends that affect companies in these industries.

For the foreseeable future, we will derive a substantial portion of our revenue from pharmaceutical and biotechnology companies. As a result, we will be subject to risks and uncertainties that affect the pharmaceutical and biotechnology industries and possible reduction and delays in research and development expenditures by companies in these industries. Our future revenues may also be adversely affected by mergers and consolidation in the pharmaceutical and biotechnology industries, which will reduce the number of potential customers.

In particular, pharmaceutical and biotechnology companies face significant regulation by governmental entities in the United States and other countries. The nature and the extent to which such regulation may apply to our customers will vary depending on the nature of any such customer's products. Most of the pharmaceutical products developed by our customers will require regulatory approval by governmental agencies prior to commercialization. In particular, human pharmaceutical therapeutic products are subject to rigorous preclinical and clinical testing and other approval procedures by the FDA and by foreign regulatory authorities. Various federal and, in some cases, state laws also govern or influence the manufacturing, safety, labeling, storage, record keeping and marketing of such pharmaceutical products. The process of obtaining these approvals and the subsequent compliance with appropriate federal and foreign statutes and regulations are time consuming, can cause significant delays in the commercialization of a drug, and often require the expenditure of substantial resources. To the extent our customers experience significant delays in obtaining the necessary regulatory approvals to market their pharmaceutical products, or are unable to obtain such approvals at all, these customers will not purchase our proprietary ligands and other services used in the manufacture of the ultimate pharmaceutical product.

We may be held liable for harm caused by drugs that our customers develop and test.

Often times, our ligands will be used by our customers to produce drugs for human use. If any of the drugs cause injuries or illness to people, we may be required to incur substantial costs in defending against claims and may be required to pay damages arising therefrom. Although we have liability insurance and will use commercially reasonable efforts to obtain indemnification covenants from our customers for their use of our products, such protections may not be sufficient to protect us from the cost of such claims. Damages awarded in a product liability action could be substantial and could have a material adverse effect on our financial condition.

We may be held liable for contamination or other harm caused by hazardous materials that we use.

Some of our research and development processes involve the use of hazardous materials and, therefore, we are subject to federal, state and local regulation governing the use, manufacture, handling, storage and disposal of hazardous materials. We cannot completely eliminate the risk of contamination or injury resulting from hazardous materials and we may incur liability as a result of any contamination or injury. We may also incur expenses relating to compliance with environmental laws. Such expenses or liability may have a material adverse effect on our financial condition.

Risks Relating to Our Technology

We may not be able to license technologies that we need to conduct our business.

In addition to the technologies that we develop, we will rely heavily on technologies that we license from other companies or institutions. We may not be able to license technologies that we need in the future or we may be unable to license such technologies on a commercially reasonable basis. Although our license agreement with the Penn State Research Foundation provides that we are entitled to use any improvements subsequently made to the technologies we currently license, the Penn State Research Foundation has no obligation to license any new technologies discovered by Dr. Zhang and researchers at Penn State. If we are unable to license the technologies we need in the future, or to license or otherwise acquire such technologies on commercially reasonable terms, we may experience increased costs (and, therefore, reduced profits) or be unable to engage in certain activities that require those technologies. Accordingly, failure to license the technologies we need in the future or otherwise acquire such technologies on commercially reasonable terms could have a material adverse effect on our business operations.

Our success will depend on our ability to protect our proprietary technology.

Our rights to a substantial portion of our technology are as the exclusive licensee to several United States patents and a number of United States and foreign pending patent applications held by the Penn State Research Foundation, including the ligands that comprise our Chiral ToolKit. These patents and patent applications are based primarily upon the work of Dr. Zhang, our chief technology officer, who is also an associate professor at the Pennsylvania State University. Our success will depend largely on our ability, and the ability of our licensors and licensees, to obtain patents for their technologies and products, if any, resulting from the application of such technologies, defend patents once obtained, and maintain trade secrets.

If we are unable to protect our intellectual property, or incur significant expense in doing so, our business, operating results and financial condition may be materially adversely affected. Any steps we take to protect our intellectual property may be inadequate, time consuming and expensive.

Our success and ability to compete are substantially dependent upon our internally developed products and services, which we currently protect through the use of United States and foreign patents. To the extent such products and services are not patentable, we will rely on trade secret protection. As with other knowledge-based products, however, our patent positions rest on complex factual and legal issues that are not entirely resolved and there can be no assurance that the patents utilized by us will adequately protect our proprietary products and services. Although we have taken steps to protect our unpatented trade secrets and know-how, in part through the control of access to such information and through the use of confidentiality agreements with our employees, consultants and certain of our contractors, customers and potential customers, there can be no assurance that these agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently developed or discovered by competitors. Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to copy or otherwise obtain and use our products or technology. We anticipate that policing unauthorized use of our products will be difficult, and we cannot be certain that the steps we intend to take to prevent misappropriation of our technology, particularly in foreign countries where the laws may not protect our proprietary rights as fully as in the United States, will be successful. Other companies may also independently develop substantially equivalent information.

Foreign laws may not afford us sufficient protection for our intellectual property rights and, in certain cases, we may not seek patent protection outside the United States.

We believe that our success will depend, in part, upon our ability to obtain international protection for our intellectual property. We have existing foreign customers and believe we will have access to large markets overseas. The laws of some foreign countries, however, may not be as comprehensive as those of the United States and may not be sufficient to protect our proprietary rights abroad. In addition, in certain cases, we may decide not to pursue patent protection outside the United States, because of cost and confidentiality concerns. Accordingly, our international competitors could obtain foreign patent protection for, and market overseas, technology for which we are seeking United States patent protection, though such competitors' patent protection generally requires such competitors to make their patent filings prior to information on our relevant inventions becoming sufficiently available under local law as to block the availability of such competitors' patent protection.

Our technology may infringe on the proprietary rights of others.

We anticipate that other patents that we license or may license in the future will be increasingly subject to infringement claims due to the rapid development of chiral chemistry and competitors in our industry. In fact, one potential competitor, Solvias, AG, based in Basel, Switzerland, notified us in July 2002 of its claim that one of the patented ligands we license from the Penn State Research Foundation infringes on a patent that Solvias licenses from BASF Group, AG. Some of our other competitors or our potential competitors may have filed or intend to file patent applications that may make claims that conflict with the claims of the patents that we license. We cannot be certain that these competitors or other third parties will not assert infringement claims against us with respect to our products and technology. Any infringement claim, regardless of its merit, could be time-consuming and expensive to defend. Such claims may also require us to enter into royalty or licensing agreements in order to continue using the disputed technology. In the event we could not afford to defend our company against an infringement claim or are not able to enter into a license or royalty agreement on commercially favorable terms, or at all, we may be required to abandon the technology that is subject to such claims.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this prospectus that are forward-looking in nature are based on the current beliefs of our management as well as assumptions made by and information currently available to management, including statements related to the markets for our products, general trends in our operations or financial results, plans, expectations, estimates and beliefs. In addition, when used in this prospectus, the words may, could, should, anticipate, believe, estimate, expect, intend, plan, predict and similar expressions and their variants, as they relate to management, may identify forward-looking statements. These statements reflect our judgment as of the date of this prospectus with respect to future events, the outcome of which are subject to risks, which may have a significant impact on our business, operating results or financial condition. You are cautioned that these forward-looking statements are inherently uncertain. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results or outcomes may vary materially from those described herein. We undertake no obligation to update forward-looking statements. The risks identified under the heading Risk Factors in this prospectus, among others, may impact forward-looking statements contained in this prospectus.

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS**

You should read the following discussion of our results of operations and financial condition in conjunction with the financial statements contained in this prospectus beginning at page F-1. This discussion includes forward-looking statements that reflect our current views with respect to future events and financial performance. We use words such as we expect, anticipate, believe, and intend and similar expressions to identify forward-looking statements. Investors should be aware that actual results may differ materially from our expressed expectations because of risks and uncertainties inherent in future events, particularly those risks identified in the Risk Factors section of this prospectus, and should not unduly rely on these forward looking statements.

Overview

Since our inception in October 2000, we have focused our efforts and resources on the development of asymmetric catalysis technology, our primary intellectual property to which we hold an exclusive worldwide license from the Pennsylvania State Research Foundation (PSRF), the technology development arm of the Pennsylvania State University (Penn State). Our license from PSRF covers certain inventions discovered by our Chief Technology Officer (CTO) prior to November 8, 2002.

Since inception we have incurred a cumulative deficit of \$3,411,205 through December 31, 2003. We expect our operating losses to increase significantly over the next several years, primarily due to expansion of our research and development programs, the hiring of additional chemists, and the expansion of our manufacturing capabilities.

Our ability to achieve profitability depends upon, among other things, our ability to discover and develop products (specifically new ligands), and to develop our products on a commercial scale through a cost effective and efficient process. To the extent that we are unable to produce, directly or indirectly, ligands in quantities required for commercial use, we will not realize any significant revenues from our technology. Moreover, there can be no assurance that we will ever achieve significant revenues or profitable operations from the sale of any of our products or technologies. Risks associated with our business are more thoroughly addressed in the section entitled Risk Factors.

Since our inception, we have generated sales revenue but not yet generated any net profits. Our management believes that our research and development (R&D) and manufacturing capacity will need to grow in order for us to be able to obtain significant licensing and manufacturing agreements with large fine chemical and pharmaceutical companies. We believe that our manufacturing capacity will be enhanced with our new office and laboratory space located in Monmouth Junction, New Jersey that was leased in June 2003.

On February 18, 2003, we acquired Surg II, Inc., a Minnesota corporation (Surg), in a reverse merger transaction (the Merger). Pursuant to the terms of the Merger, Chiral Quest, LLC merged with and into a wholly-owned subsidiary of Surg. In exchange for all of the outstanding membership interests of Chiral Quest, LLC, Surg issued to the former members of Chiral Quest, LLC a number of shares of Surg's common stock that resulted in the members of Chiral Quest, LLC owning two-thirds of Surg's outstanding shares following the Merger. In connection with the Merger, Surg changed its name to Chiral Quest, Inc., a Minnesota corporation, and adopted the business plan of Chiral Quest, LLC. Accordingly, when we refer to our business or financial information relating to periods prior to the Merger, we are referring to the business and financial information of Chiral Quest, LLC, unless the context indicates otherwise.

Results of Operations Years Ended December 31, 2003 vs. 2002

Our revenues for the year ended December 31, 2003 were \$669,036 as compared to \$191,613 for the year ended December 31, 2002. For the year ended December 31, 2003, approximately 20% of total revenue was derived from the amortization of option fee income pertaining to the licensing of our intellectual property and 80% of total revenue was derived from sales of our ligands, feasibility screening and customized process development services sold to third parties. For the year ended December 31, 2002, approximately 86% of total revenue was derived from the amortization of option fee income and 14% of total revenue was comprised of sales of our ligands. It is anticipated that sales of our ligands, molecular building blocks and customized chiral services will continue to comprise a greater percentage of our revenues in the future as we expand our manufacturing capabilities.

Cost of goods sold for the year ended December 31, 2003 was \$196,045 as compared to \$6,763 during the year ended December 31, 2002. The increase of Cost of goods sold is attributed to the allocation of direct labor, and overhead expenses to finished goods. These expenses were allocated from compensation and rent expenses as part of overall general operating expenses.

Management and consulting expenses for the year ended December 31, 2003 were \$361,622 as compared to \$231,424 during the year ended December 31, 2002. The overall change for the year ended December 2003 vs. 2002 was primarily caused by an increase in consulting expense. Consulting expense increased due to the new consultant agreement entered with our CTO at a rate of \$10,000 per month effective May 15, 2003. In addition, consulting expense increased from the amortization of stock options issued to consultants, scientific advisory board members, during the second, third and fourth quarters of 2003.

Our R&D expenses for the year ended December 31, 2003 were \$440,646 as compared to \$63,728 during the year ended December 31, 2002. This increase was primarily caused by increased utilization of the Penn State research resources in connection with the development of new ligands. The agreement with Penn State requires us to fund services of four post-doctorate fellows who, under the supervision of the CTO, conducted research and provided research quantities of chiral ligands to us. This agreement has been extended to April 14, 2004. The approximate obligation payable by us through the end of the agreement dated April 14, 2004, is approximately \$96,000. This amount consists principally of four post-doctorate salaries, fringe benefits, materials and supplies for the stated period. In addition, during the second quarter of 2003, we opened an additional laboratory facility that enabled us to produce both research and commercial quantities of our ligands. In connection with the new facility, numerous lab supplies and chemicals were purchased. Accordingly, we incurred significant R&D expenses in the fourth quarter due to the opening of the New Jersey facility, along with the increased costs of using the facility and chemists at Penn State.

Selling, general and administrative (SG&A) expenses for the year ended December 31, 2003 were \$1,012,182 as compared to \$193,449 during the year ended December 31, 2002. This increase in SG&A expenses was due in part to higher legal and accounting fees associated with our reporting obligations as a public company, increased rent expense for the New Jersey facility, additional spending on advertising and promotion expenses, increased travel expenses for new business development opportunities and higher administrative expenses associated with having more employees such as insurance and employer payroll taxes.

Compensation expense was \$601,780 for the year ended December 31, 2003 as compared to \$197,596 for the year ended December 31, 2002. This increase was caused primarily by the new CEO (hired in November 2002) receiving an annual base salary of \$205,000 effective at the date of the Merger with Surg II, Inc., as provided for in his employment agreement. In addition, compensation expense increased due to the hiring of a vice president of business development, a controller, and several chemists to work at the new laboratory facility in New Jersey. Compensation expense as it relates to direct labor for ongoing and completed projects, has been capitalized as part of inventory work in process and finished goods as these cost components relate directly to cost of goods sold.

Depreciation and amortization expenses for the year ended December 31, 2003 were \$86,325 as compared to \$36,631 during the year ended December 31, 2002. This increase was primarily related to fixed asset purchases for office equipment, computer equipment, laboratory equipment and leasehold improvements for the newly leased facility in New Jersey.

Interest expense for the year ended December 31, 2003 was \$2,809 as compared to \$0 during the year ended December 31, 2002. The interest expense for the year ended December 31, 2003 is attributed to the promissory notes issued between July 2002 through February 2003 owed to a related party, which were fully paid and discharged in February 2003.

Interest income for the year ended December 31, 2003 was \$13,973 as compared to \$0 during the year ended December 31, 2002. The increase in interest income was caused by significantly higher cash reserves obtained after the Merger on February 18, 2003.

Our net loss for the year ended December 31, 2003 was \$2,018,400 as compared to \$537,978 for the year ended December 31, 2002. The increased net loss for the year ended December 31, 2003 as compared to December 31, 2002 was primarily due to higher R&D expenses incurred with Penn State, increased legal and accounting expenses in reporting as a public company, along with other SG&A expenses such as higher payroll expenses associated with having more employees. We expect losses to continue and increase in the next year as we attempt to expand our laboratory space, purchase more chemicals and raw material compounds, and hire additional employees.

Results of Operations Years Ended December 31, 2002 vs. 2001

Our revenues for the year ended December 31, 2002 were \$191,613 as compared to \$167,683 for the year ended December 31, 2001. The revenues are comprised primarily of the licensing of PSRF's technology. We assume the financial risks related to these revenues by financing the research and development of PSRF's technology as well as the defense of PSRF's patents. The increase of approximately 14% from December 31, 2001 can be attributed to our January 2002 agreement with a pharmaceutical product development customer, granting the customer a worldwide, non-exclusive, royalty free license to certain of our intellectual property rights for research purposes only in connection with certain of the customer's compounds. The customer paid us a nonrefundable license fee of \$400,000 in 2002. The fee is being amortized to revenue through September 2005. For the year ended December 31, 2002 approximately 86% of total revenue was derived from the amortization of option fee income pertaining to the licensing of our intellectual property and 14% of total revenue was derived from sales of our ligands, feasibility screening and customized process development services sold to third parties. For the year ended December 31, 2001, approximately 25% of total revenue was derived from the amortization of option fee income and 75% of total revenue was comprised of sales of our ligands. It is anticipated that sales of our ligands, molecular building blocks and customized chiral services will continue to comprise a greater percentage of our revenues in the future as we expand our manufacturing capabilities.

Cost of goods sold for the year ended December 31, 2002 was \$6,763 as compared to \$0 during the year ended December 31, 2001. The increase of cost of goods sold is attributed to allocating material costs to specific projects as part of finished goods during the year ended December 31, 2002, as compared to expensing materials, laboratory chemicals and supplies as part of operating expenses during the year ended December 31, 2001.

Management and consulting expense fees for the year ended December 31, 2002 were \$231,424 as compared to \$261,600 during the year ended December 31, 2001. The overall change for the years ended December 2002 vs. 2001 was primarily caused a decrease in utilizing outside consulting services related to the business operations.

Our R&D expenses for the year ended December 31, 2002 were \$63,728 as compared to \$224,592 during the year ended December 31, 2001. This change was primarily caused by increased laboratory supplies and chemicals purchased during the year ended 2001 in connection with the development of new ligands.

SG&A expenses for the year ended December 31, 2002 were \$193,449 as compared to \$137,371 during the year ended December 31, 2001. SG&A expenses increased due to having more employees contributing to costs such as insurance, employer payroll taxes, office expenditures and travel.

Compensation expense was \$197,596 for the year ended December 31, 2002 as compared to \$111,706 for the year ended December 31, 2001. This increase was caused primarily in the hiring of additional chemists to work at our State College, Pennsylvania (at Penn State University) laboratory facility.

Bad debt expense was \$0 for the year ended December 31, 2002 as compared to \$50,000 for the year ended December 31, 2001. During the year ended December 31, 2001, we established a reserve for an international client who provided no assurance of collectibility.

Depreciation and amortization expenses for the year ended December 31, 2002 were \$36,631 as compared to \$24,611 during the year ended December 31, 2001. This increase was primarily related to fixed asset purchases for office equipment, computer equipment, and laboratory equipment, for our State College office.

Interest income for the year ended December 31, 2002 was \$0 as compared to \$1,804 during the year ended December 31, 2001. The decrease in interest income in 2002 was caused by lower cash reserves during the year ended December 31, 2002.

Our net loss for the year ended December 31, 2002 was \$537,978 as compared to \$640,393 for the year ended December 31, 2001. The higher loss for the year ended December 31, 2001 as compared to December 31, 2002 was primarily due to higher R&D expenses incurred with the purchases of laboratory supplies and chemicals, management and consulting fees, along with establishing the reserve for bad debt during the year ended December 31, 2001.

Liquidity and Capital Resources

As of December 31, 2003, we had working capital of \$116,359 and cash and cash equivalents of \$659,117. If we are unable to significantly increase our revenues, we will most likely require additional financing by the end of the first quarter of 2005 in order to continue operations. The most likely source of financing includes private placements of our equity or debt securities or bridge loans to the Company from third party lenders.

Our net cash used in operating activities for the year ended 2003 was \$1,636,934. Our net loss of \$2,018,400 was offset by an increase of accounts payable and accrued expenses of \$161,582 and \$112,481 respectively, along with depreciation and amortization of approximately \$324,000.

Our net cash used in investing activities for the year ended 2003 was \$368,087. Investing activities expenditures consisted of purchases of property and equipment of \$237,222 and payments for intellectual property rights of \$130,865.

Our net cash provided by financing activities for the year ended 2003 was \$2,630,618. Financing activities included the repayment of a note payable to Paramount of \$376,625 along with cash received in the merger dated February 18, 2003 in the amount of \$3,017,243.

In February 2004, we completed the sale of our securities in a private placement to accredited investors for gross proceeds of approximately \$7.2 million. Management believes that the capital resulting from this financing will provide sufficient resources to fund our continued operational expansion and corporate development for more than the next twelve months. Our long term liquidity is contingent upon achieving sales and/or obtaining additional financing.

Our working capital requirements will depend upon numerous factors, including without limitation the progress of our R&D programs, the resources we devote to developing manufacturing and marketing capabilities, technological advances, the status of competitors, and our ability to establish sales arrangements with new customers. Working capital will also be affected by the expansion of office and laboratory space lease agreements that were entered into during the second quarter of 2003 and first quarter of 2004, along with the hiring of additional employees.

We have formed two China subsidiaries through which we intend to open a laboratory facility in the People's Republic of China. We expect to provide at least \$65,000 of capital to the China subsidiary during the second quarter of 2004. Our management believes that by opening a facility in China to produce non-proprietary chemical building blocks and related compounds, we will be able to significantly decrease our manufacturing costs and expenses, which will enable us to cost-effectively produce our ligands and end products and make our products substantially more competitive and even more attractive to current and potential customers. We expect operations to commence on a limited basis by June 2004.

Critical Accounting Policies

Impairment of Intellectual Property Rights

We evaluate the recoverability of its long-lived assets, where indicators of impairment are present, by reviewing current and projected profitability or undiscounted cash flows of such assets. Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Intangible assets not subject to amortization are tested for impairment at least annually. For the years ended December 31, 2003 and 2002, we determined that impairment to our long-lived assets did not occur. Accordingly, no impairment loss was recorded for the years ended December 31, 2003 and 2002.

Revenue Recognition

Revenues are comprised principally of four main components: (1) the licensing of PSRF's technology, (2) the sale of proprietary ligands, (3) feasibility screening, and (4) custom contract development. Revenues as they relate to the licensing of our rights to PSRF's intellectual property are recognized upon over the applicable license periods. We assume the financial risks related to these revenues by financing the research and development of PSRF's technology as well as the defense of PSRF's patents. Deferred revenue in the accompanying consolidated balance sheets represents amounts prepaid by customers to us for services to be performed and products to be delivered at a subsequent date. These deferred amounts will be recognized as revenue when earned. Revenues as they relate to the sale of manufactured proprietary ligands are recognized upon the shipping of the ligands to the customer. Revenues as they relate to feasibility screening are recognized upon the completion of project reports and investigational studies. Revenues as they relate to custom contract development are recognized upon the shipment of finished products.

Accounting for Stock-Based Compensation

We account for our employee and director stock option plans in accordance with APB Opinion No. 25, *Accounting For Stock Issued To Employees*, and related interpretations. We measure compensation expense for employee and director stock options as the aggregate difference between the market value of its common stock and exercise prices of the options on the date that both the number of shares the grantee is entitled to receive and the exercise prices are known. Compensation expense associated with restricted stock grants is equal to the market value of the shares on the date of grant and is recorded pro rata over vesting period.

Recently Issued Accounting Standards

In July 2002, the FASB issued SFAS No. 146, *Accounting for Restructuring Costs*. SFAS No. 146 applies to costs associated with an exit activity (including restructuring) or with a disposal of long-lived assets. Those activities can include eliminating or reducing product lines, terminating employees and contracts and relocating plant facilities or personnel. Under SFAS No. 146, we will record a liability for a cost associated with an exit or disposal activity when that liability is incurred and can be measured at fair value. SFAS No. 146 will require us to disclose information about our exit and disposal activities, the related costs, and changes in those costs in the notes to the interim and annual financial statements that include the period in which an exit activity is initiated and in any subsequent period until the activity is completed. SFAS No. 146 is effective prospectively for exit or disposal activities initiated after December 31, 2002, with earlier adoption encouraged. Under SFAS No. 146, a company cannot restate previously issued financial statements and the new statement grandfathers the accounting for liabilities that a company had previously recorded under Emerging Issues Task Force Issue 94-3.

In December 2002, the FASB issued SFAS No. 148, *Accounting for Stock-Based Compensation-Transition and Disclosure - an amendment of FASB Statement No. 123*. SFAS No. 148 amends SFAS No. 123, *Accounting for Stock Based Compensation* and provides alternative methods for accounting for a change by registrants to the fair value method of accounting for stock-based compensation. Additionally, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require disclosure in the significant accounting policy footnote of both annual and interim financial statements of the method of accounting for stock based-compensation and the related pro-forma disclosures when the intrinsic value method continues to be used. SFAS No. 123 is effective for fiscal years beginning after December 15, 2002, and disclosures are effective for the first fiscal quarter beginning after December 15, 2002.

In May 2003, the FASB issued SFAS No. 150, *Accounting For Certain Financial Instruments with Characteristics of both Liabilities and Equity*. SFAS No. 150 changes the accounting for certain financial instruments with characteristics of both liabilities and equity that, under previous pronouncements, issuers could account for as equity. The new accounting guidance contained in SFAS No. 150 requires that those instruments be classified as liabilities in the balance sheet.

SFAS No. 150 affects the issuer's accounting for three types of freestanding financial instruments. One type is mandatorily redeemable shares, which the issuing company is obligated to buy back in exchange for cash or other assets. A second type includes put options and forward purchase contracts, which involves instruments that do or may require the issuer to buy back some of its shares in exchange for cash or other assets. The third type of instruments that are liabilities under this Statement is obligations that can be settled with shares, the monetary value of which is fixed, tied solely or predominantly to a variable such as a market index, or varies inversely with the value of the issuer's shares. SFAS No. 150 does not apply to features embedded in a financial instrument that is not a derivative in its entirety.

Most of the provisions of SFAS No. 150 are consistent with the existing definition of liabilities in FASB Concepts Statement No. 6, Elements of Financial Statements. The remaining provisions of this Statement are consistent with the FASB's proposal to revise that definition to encompass certain obligations that a reporting entity can or must settle by issuing its own shares. This Statement shall be effective for financial instruments entered into or modified after May 31, 2003 and otherwise shall be effective at the beginning of the first interim period beginning after June 15, 2003.

We believe that the adoption of these pronouncements will not have a material impact on our consolidated financial position or results of operations.

OUR COMPANY

Overview

We are a research-driven company engaged in the commercial development of asymmetric products and technology for the life sciences industry. We have two main lines of products and services – proprietary chiral catalysts and chiral building blocks or client-defined molecules. We have the rights to certain chemical compounds known as chiral ligands which, with the introduction of a metal, serve as catalysts in facilitating the production of chiral molecules in such a manner that there is a preferential manufacture of the desired molecule versus the unwanted mirror-image molecule. We provide pharmaceutical and fine chemical manufacturers and other prospective clients with broad access to our technologies for testing purposes at a low upfront cost, coupled with the opportunity to gain access to such technologies for specific applications for fees, royalties and certain manufacturing and development rights. Our ligands may also find use in producing fine chemicals other than pharmaceuticals; -chiral molecules are used in flavors, fragrances, agrochemicals, animal health, food and feed additives (including vitamins) and nutraceuticals. In connection with our chiral technology, we provide specialized services to pharmaceutical, biotechnology and fine chemical companies relating to the development of chiral manufacturing processes for their products.

Our proprietary technology was developed by Dr. Xumu Zhang, a professor at Pennsylvania State University (Penn State) and is owned by the Penn State Research Foundation (PSRF), the technology development arm of Penn State. In November 2000, we obtained from the PSRF an exclusive, worldwide license to certain patents based on Dr. Zhang 's research relating to asymmetrical catalysis. This license gives us the right to, among other things, sub-license technology rights on a non-exclusive basis to clients, or sell molecule groups, known as ligands, to pharmaceutical and fine chemical company clients for both research and commercial applications.

Chiral Quest is also engaged in developing and making client-defined building blocks and drug candidate fragments, mainly in the chiral area. With this process chemistry offering to life sciences companies, we develop new synthetic routes or optimize existing ones and produce certain quantities of material for further processing at the clients ' needs either for further elaboration, clinical trials or beyond.

Chiral Quest, Inc., a Minnesota corporation, resulted from the reverse merger of Chiral Quest, LLC, a Pennsylvania limited liability company that commenced operations in October 2000, and Surg II, Inc., a Minnesota corporation, on February 18, 2003.

Chiral Chemistry

Over 50 percent of the 500 top-selling pharmaceutical drugs on the market are comprised of chiral molecules, including drugs used to treat anxiety, depression, indigestion, heartburn, cancer, arthritis, AIDS and allergies. In 2003, chiral drug sales were over \$160 billion, based on a report in *Chemical and Engineering News* of the American Chemical Society, which represents over one third of the complete drug market of over \$410 billion. The majority of new drug candidates under development by pharmaceutical companies consist of chiral chemicals.

A molecule is considered chiral because it exists in two enantiomers, or non-superimposable mirror-like images analogous to one's left and right hands. Most drugs interact with biological targets in a specific manner, requiring the drug to be of a specific shape and orientation. Contaminating wrong-handed enantiomers of the active drug molecule will probably not interact with the biological drug target, or worse, interact with a different biological molecule in an unintended and often toxic manner. Thalidomide, the morning sickness drug used by pregnant women in the 1960s, is a notorious example of an impure chiral drug. One enantiomer of the drug's chiral molecules treated morning sickness, while its undesired enantiomer impurity caused birth defects. Pharmaceutical companies are typically required, at great expense, to purify the active mirror-image form of the drug molecule away from its contaminating or inactive counterpart.

Products and Services

We offer two business lines, one in products and one in services in order to provide clients with critical solutions for the efficient manufacturing of chiral products or therapeutic drugs. Our products include bulk chiral catalysts, proprietary building blocks / client-defined targets and a proprietary Chiral ToolKit, comprised of a diverse set of chiral ligands that are combined with transition metals to catalyze reactions leading to chiral molecules. We also offers a variety of services covering specialized chiral transformation screening, chiral synthetic or process support and manufacturing solutions to be delivered on a partnership/contract basis with client firms. Our products and services are applicable throughout the full life cycle of a chiral drug, from early lead discovery, through development and in commercialization.

The CQ Chiral Library depicted below identifies the current portfolio of proprietary ligands from which clients order both the Chiral ToolKit selection sets for R&D testing as well as bulk quantities for larger scale uses and commercialization.

Chiral ToolKit. We currently sell products which represent several of the proprietary families of our chiral ligands to which we have exclusive rights. These ligands are sold in research quantities packaged in convenient Chiral ToolKit sets for exclusive use in research applications by client companies. These innovative, patent protected ligands are screened by clients for applications in the manufacture of their chiral molecules. Clients use this screening process to determine which ligands may prove optimal for their chiral manufacturing needs. The sale of research quantities of ligands allows clients to gain initial access to our technology and to independently validate the advantages provided by that technology.

Bulk Ligands. We also sell larger quantities of proprietary chiral ligands to which we have exclusive rights, including some that are not included in our Chiral ToolKit. These ligands are sold individually to clients in amounts specified by the client according to its research, development or semi-commercial needs. One of our objectives is to provide clients with their required ligands and catalysts, either from our own laboratories or through third parties, for research, clinical and commercial purposes. The use of CQ bulk ligands in commercial drug applications will generally require license fees and/or other related payments to us, subject to negotiation.

Screening Services. We also provide focused screening of client supplied target compounds using our proprietary ligands. In addition to the select ligands included in the Chiral ToolKit, we have several families of chiral ligands that are used to screen target compounds. We identify and prepare individual ligands optimized for particular client needs.

Proprietary Building Blocks / Client-Defined Targets. We work with our clients to help optimize the conditions under which our ligands are used and also produce certain molecules of customer interest. This may involve the development of novel manufacturing processes, for which we will derive additional compensation. We may also structure our client agreements to assure the use of our ligands within the manufacturing process, thereby requiring our customers to buy the ligands from us in commercial quantities in order for the client to successfully manufacture its compound. We may also produce and sell certain selected chiral products defined by our clients such as chiral building blocks or intermediates.

Strategy

Our business strategy is focused on exploiting our asymmetric catalysis technology by:

- Focusing our research group on designing and discovering additional commercially useful ligands and manufacturing processes;
- Providing screening services necessary to test the selectivity and activity of a broad portfolio of proprietary technologies for client substrates;
- Granting access to a selection of our ligands through non-exclusive licenses for research and development purposes;
- Granting compound-specific exclusive rights to clients whose businesses require commercial use of one or more of our ligands;
- Developing proprietary process methods for producing chirally pure pharmaceutical ingredients, intermediates and building blocks in exchange for fees, milestone payments and royalties; and
- Assisting clients in the development of chiral drugs, the development of which has been slowed or halted due to manufacturing inefficiencies, which are amenable to improvements through our technology.

Sales and Marketing

We sell our products and services directly to clients both in the pharmaceutical and fine chemical areas. In October 2003, we hired a senior executive who is focused on sales and marketing activities. We intend to hire additional marketing personnel in the near future.

Dependence on Certain Customers

In fiscal 2003, we had two customers that accounted for approximately 54 percent and 17 percent of our revenue, respectively. The loss of these accounts would have a material adverse effect on our business; however, we believe our relationships with these customers are strong.

Competition

Competition in the traditional area of separation manufacture of chiral molecules comes from a few distinct sources, including Chiral Technologies Inc., ChromTech Ltd., NovaSep, Inc. and Advance Separation Technologies Inc. Traditional methods of manufacturing chiral molecules involve the production of a mixture of both chiral forms of molecules of interest, followed by a process which separates the desired enantiomer from the undesired enantiomer. This methodology, though still commonly used, is extremely cost-ineffective, as it results in the loss of greater than 50 percent of the intermediate product at each chiral purification step. We believe we have a competitive advantage over companies using traditional methods of separation because our technology drives the preferential manufacture of chiral enantiomers of interest, which can result in 95 to 99 percent yields. This can result in significant cost savings in the manufacturing process, particularly for chiral molecules that may require several chiral separation steps by traditional methods.

In the area of chemical catalysts for chiral drug manufacture, we compete with pharmaceutical and fine chemical companies, including our current and potential clients and collaborators, academic and research institutions. Some of these companies include the Dow Chemical Company, Degussa AG, Rhodia ChiRex Inc. and Solvias AG. Many of these companies are developing or marketing technologies and services similar to the ones developed or offered by us. We anticipate continued competition from other manufacturers of chiral catalysts in the future.

Some of our competitors, such as Codexis, a wholly owned subsidiary of Maxygen, or Diversa Corporation, attempt to genetically modify biological enzymes for the purpose of serving as biological catalysts for asymmetric chiral manufacturing. While this approach works in certain circumstances, it is extremely time-consuming to develop for each individual manufacturing process. We believe our technology has the competitive advantage of being more broadly applicable to a number of common asymmetric transformations.

Intellectual Property

License with the Penn State Research Foundation. We have an exclusive, worldwide license from the PSRF to certain chiral technologies developed by Dr. Zhang. The license agreement has been amended on five occasions, four of which provide us with additional rights, including the rights to new patent applications. The PSRF license agreement grants us rights to any conversions, re-issues, extensions, divisional applications, continuations, continuations in part, and any patents issuing thereon, and any improvements to the licensed patents. Under the license agreement, PSRF received an equity stake in our company as partial consideration for the license. The license agreement also obligates us to reimburse PSRF for its patent expenses relating to the licensed technology.

The PSRF license agreement requires us to use our reasonable best efforts to achieve annual gross revenue of \$250,000 in calendar year 2004, \$350,000 in calendar year 2005, and \$500,000 in calendar year 2006. Should we fail to obtain these milestones, PSRF has the right, but not the obligation, to terminate the license agreement on the grounds that we failed to use our best efforts to achieve those milestones.

Additionally, in accordance with the license agreement, PSRF's obligation to license to us, at no additional cost, any new technology subsequently discovered by Dr. Zhang and the other researchers at Penn State expired on November 8, 2002. Accordingly, if Dr. Zhang develops a new invention that does not constitute an improvement on the existing patent rights, then we will have to license the right to such invention from the Penn State Foundation.

Patents. We have an exclusive license 13 United States patent applications filed by the PSRF covering many classes of ligands. The U.S. Patent and Trademark Office ("PTO") has issued seven (7) letters patents in connection with these applications (i.e., U.S. Pat. Nos. 6,380,392, 6,525,210, 6,521,769, 6,337,406, 6,576,772, 6,534,657 and 6,653,485). In addition, the PTO has issued notices of allowance on one (1) other application for which we anticipate a patent being issued in 2004. The remaining five (5) patent applications are still pending. We also have rights to international patent applications based on many of the US application filings. National Phase Applications have been filed for six (6) international applications (PCT) corresponding to the originally filed U.S. applications.

Employees and Consultants

We currently employ 11 people: Ronald Brandt, our VP of Business Development and interim CEO, Brian Lenz, our interim Chief Financial Officer, Yaping Hong, our interim Chief Operating Officer, and 8 full time chemists. We also engage Dr. Zhang, who serves as our Chief Technology Officer, on a consultancy basis. Additionally, we fund four post-doctoral fellows, under the supervision of Dr. Zhang, pursuant to an agreement with Penn State. Of the 16 persons providing services to our company, either as employees or consultants, 8 hold Ph.D. degrees. As we develop our technology and business, we anticipate the need to hire additional employees, especially employees with expertise in the areas of chemistry and sales and marketing.

Facilities

Our management believes that our facilities are adequate for our current needs, including the production of research and commercial quantities of our ligands, and the needs of our company for at least the next 12 months. However, we anticipate leasing or purchasing additional laboratory facilities as our business matures.

Monmouth Junction, New Jersey. We lease our principal executive offices located in Monmouth Junction, New Jersey. This facility consists of 5,000 square feet of mostly laboratory space with some additional office space at which our Controller and Vice President of Business Development maintain offices. Eventually, we expect that this facility will office our entire senior executive team. We occupy this facility pursuant a March, 2003 lease agreement, pursuant to which we pay approximately \$13,000 per month for rent, utilities, and maintenance fees. The lease expires in April 2006. We use this facility to produce both research and commercial quantities of our ligands and finished products. In February 2004, we amended our lease agreement for our Monmouth Junction facility to add another 1,200 square feet of laboratory space in order to increase our capacity to produce research and commercial quantities of our ligands. We expect this additional space to be available by April 2004. The additional lease space will increase our monthly rent by approximately \$2,000.

State College, Pennsylvania. We maintain an additional 889 square feet of office and laboratory space at 1981 Pine Hall Drive in State College, Pennsylvania. We lease this facility pursuant to a lease agreement with the Penn State Research Foundation pursuant to which we are required to pay annual payments of approximately \$15,000. Currently, this facility is home to our director of operations, Dr. Zhang and two chemists whose efforts are primarily devoted to providing our screening services. Our lease for this facility expires in January 2005.

New York, New York. Our President and Chief Executive Officer also maintains an executive office at 787 Seventh Avenue in New York City within the office of Paramount BioCapital Investments, LLC. We occupy this space on a month-to-month basis at a cost of \$4,000 per month, which also includes general and administrative services provided by Paramount BioCapital Investments, LLC.

The People's Republic of China. Pursuant to an agreement with the Science and Technology Bureau of Jiashan County (Jiashan) in Zhejiang Province of the People's Republic of China, we have agreed to lease a total of 4,000 square meters of laboratory space in an industrial park near Shanghai, 15-20 percent of which we will begin occupying in 2004. Jiashan is currently building this facility to specifications and we expect to occupy the facility in the third quarter of 2004. Pursuant to our agreement with Jiashan, although we are not required to pay rent during the initial 3-years of the lease, we will pay a maintenance fee of up to \$4,500 per month. Following the initial 3-year term, we may, at our sole discretion, either continue leasing the space for annual rent of no more than \$60,000 (at approximate conversion rate as of December 31, 2003) or to purchase the facility on commercially reasonable terms. We were also granted the option to purchase in the next three years approximately 33 acres of land adjacent to the industrial park. For purposes of entering into the lease, we established a wholly owned subsidiary organized under the laws of Hong Kong, known as Chiral Quest Ltd., which in turn will be the sole shareholder of a subsidiary in the People's Republic of China, Chiral Quest (Jiashan) Ltd.

Legal Matters

We are not a party to any material litigation and are not aware of any threatened litigation that would have a material adverse effect on our business.

MANAGEMENT

Our executive officers and directors are described below. There are no family relationships among our executive officers or directors.

Name	Age	Positions
Ronald Brandt	56	Interim CEO and Vice President of Business Development
Yaping Hong	48	Interim Chief Operating Officer
Xumu Zhang, Ph.D.	46	Chief Technology Officer and Director
Brian Lenz	31	Interim Chief Financial Officer and Secretary
Stephen C. Rocamboli	32	Interim Chairman
Vincent Aita, Ph.D.	30	Director
Kenneth W. Brimmer	48	Director
Stephen A. Roth, Ph.D.	61	Director
David M. Tanen	32	Director
Michael Weiser, M.D., Ph.D	40	Director

Ronald Brandt has been our Vice President of Business Development since October 2003 and was appointed interim Chief Executive Officer in April 2004. Prior to joining us, he was Executive Vice President of Marketing & Sales at Ricerca Biosciences from October 2002 to August 2003. Previous to Ricerca Biosciences, Mr. Brandt held senior Sales and Business Development positions at ISP (International Specialty Products) from October 1997 to July 2002. From November 1972 to January 1997, Mr. Brandt was employed by Lonza Group in the U.S. and Europe, eventually serving as Senior Vice President from June 1988 to January 1997. He holds a Bachelors of Engineering, specializing in Chemical Engineering, from the Cooper Union, NY and an M.B.A. from Rutgers University in New Jersey.

Yaping Hong, Ph.D., has served as our Director of Process Research and Development since May 2003 and was appointed interim Chief Operating Officer in April 2004. Prior to joining our company, Dr. Hong was Director of Process Chemistry for Synthron Chiragenics from August 2001 to May 2003. From April 1993 to August 2001, Dr. Hong was employed by Sepracor Inc., eventually serving as Associate Research Fellow from January 2001 to August 2001. Dr. Hong holds a Ph.D. in Synthetic Organic Chemistry from the University of Waterloo. Dr. Hong conducted his postdoctoral work from September 1991 to March 1993 at the Massachusetts Institute of Technology, in Cambridge Massachusetts.

Xumu Zhang, Ph.D., a co-founder of our company, has been a member of our board of directors and has served as our Chief Technology Officer and as a consultant since our inception in 2000. Since 1994, Dr. Zhang has been primarily employed by Pennsylvania State University in State College, Pennsylvania, most recently as a Professor of Organic Chemistry, and prior to that was an Assistant and Associate Professor of Chemistry. Dr. Zhang holds a Ph.D. in Organic and Inorganic Chemistry from Stanford University, where he also conducted his postdoctoral work.

Brian Lenz joined our company as our Controller in October 2003 and was subsequently appointed to the offices of Secretary in January 2004 and interim Chief Financial Officer in April 2004. Previously, he was Controller of Smiths Detection from July 2000 to September 2003. Mr. Lenz was a Senior Auditor at KPMG LLP from October 1998 to June 2000. Mr. Lenz is a Certificated Public Accountant, holds a Bachelors of Science in Business Administration from Rider University in New Jersey, and an M.B.A. from Saint Joseph's University in Pennsylvania.

Stephen A. Roth, Ph.D., has served as a member of the board of directors since February 2003. Dr. Roth is currently President, CEO, and director of Immune Control, Inc. Prior to joining Immune Control, Dr. Roth co-founded Neose Technologies in 1990, becoming its Chief Executive Officer and Chairman in 1994. Prior to starting Neose, Dr. Roth was assistant and associate professor of biology at The Johns Hopkins University from 1970-1980. He moved to the University of Pennsylvania as professor of biology in 1980, and was appointed Department Chairman in 1982, serving in that role until 1987. At Penn, Dr. Roth helped form its Plant Science Institute. His scholarly interests centered on the roles of complex carbohydrates in embryonic morphogenesis and in malignancy, topics on which he authored or co-authored nearly 100 articles and one book. He has received several research awards and prizes, and is an inventor on 18 patents and six patent applications. Dr. Roth received an A.B. degree from Johns Hopkins in 1964, a Ph.D. from Case Western Reserve University in 1968, and did postdoctoral work in carbohydrate chemistry at Hopkins from 1968-1970.

Stephen C. Rocamboli has served as our Interim Chairman since February 2003, and our Secretary from February 2003 until December 2003. Since September 1999, Mr. Rocamboli has been deputy general counsel of Paramount BioCapital, Inc. and Paramount BioCapital Investments, LLC. From November 2002 to December 2003, Mr. Rocamboli served as a director of Ottawa, Ontario based Adherex Technologies, Inc. Mr. Rocamboli also serves as a member of the board of directors of several privately held development stage biotechnology companies. Prior to joining Paramount, Mr. Rocamboli practiced law in the health care field. He received his J.D. from Fordham University School of Law.

Vincent M. Aita, Ph.D. has been a director of our company since February 2003. Since February 2004, Dr. Aita has been an analyst for Kilkenny BioCapital Management, LLC. Prior to that, he was a research analyst for Paramount BioCapital Asset Management, Inc. from November 2000 to January 2004. Prior to that, Dr. Aita completed a post-doctoral fellowship in the Department of Genetics and Development at Columbia University, and concurrently served as a scientific consultant for Research Assessment Associates, Inc. From August 1995 to December 1999, Dr. Aita attended Columbia University where he received a Ph.D. in Genetics from the Columbia Genome Center.

Kenneth W. Brimmer has served as a member of the board of directors since February 2003. Mr. Brimmer has been chief manager of Brimmer Company, a private investment company he founded, since December 2001. Since September 2003, he has been Chief Executive Officer of Sterion, Incorporated, a Minneapolis based medical products company, and has served as its Chairman since March 2000. From April 2002 to February 2003 he served as Chairman and Chief Executive Officer of Surg II, Inc., with whom we completed a reverse merger transaction in February 2003. From March 2000 to December 2001 Mr. Brimmer was Chief Executive Officer and Chief Financial Officer of Minnetonka, Minnesota-based Active IQ Technologies, Inc. (nka Wits Basin Precious Minerals Inc. and served as its Chairman from April 2000 to June 2003. From May 1995 until April 2000, Mr. Brimmer was Treasurer of Rainforest Café, Inc., and served as that company's President from April 1997. From 1990 until 1997, Mr. Brimmer was also engaged in an executive position with Minneapolis-based Grand Casino, Inc. Mr. Brimmer is currently the chairman of the board of directors of Sterion Incorporated and Entrx Corporation, and is a director of Hypertension Diagnostics, Inc., all publicly-held companies. Mr. Brimmer began his career as a Certified Public Accountant.

David M. Tanen has served as a member of the board of directors since February 2003. He has been employed primarily as an associate director of Paramount BioCapital, Inc. and Paramount BioCapital Investments, LLC since 1996, where he has assisted in the founding of a number of biotechnology start-up companies. Since January 2002, Mr. Tanen has served as a director of Manhattan Pharmaceuticals, Inc. (OTCBB: MHTT), a company engaged in the development of early stage pharmaceutical technologies. Mr. Tanen also serves as a director of several privately held development stage biotechnology companies. Mr. Tanen received his J.D. from Fordham University School of Law.

Michael Weiser, M.D., Ph.D., has served as a member of the board of directors since February 2003. Dr. Weiser concurrently serves as the Director of Research of Paramount BioCapital Asset Management. Since February 2003, Dr. Weiser has also served as director of Manhattan Pharmaceuticals, Inc. (OTCBB: MHTT), a company engaged in the development of early-stage pharmaceutical technologies. Dr. Weiser is also a member of Orion Biomedical GP, LLC, and serves on the board of directors of several privately held companies. Dr. Weiser holds an M.D. from New York University School of Medicine and a Ph.D. in Molecular Neurobiology from Cornell University Medical College. Dr. Weiser completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience at New York University School of Medicine and performed his post-graduate medical training in the Department of Obstetrics and Gynecology and Primary Care at New York University Medical Center.

Code of Ethics

We currently do not have a Code of Ethics that applies to our President, Chief Executive Officer & Chief Financial Officer and our Controller. Our management is currently in the process of developing a policy and expects to present it to our Board of Directors for review and approval during the second quarter of 2004. Once we have adopted a code, we will provide a copy of the Code of Ethics without charge upon written request directed to Brian Lenz, 7 Deer Park Drive, Suite E, Monmouth Junction, NJ 08852.

Audit Committee Financial Expert

We have an Audit Committee composed of Messrs. Brimmer, Rocamboli and Tanen and have determined that Mr. Brimmer qualifies as an audit committee financial expert, as that term is defined by SEC regulations. As indicated above, Mr. Brimmer has previous experience as a certified public accountant. Although our common stock is not listed on any of the New York Stock Exchange, American Stock Exchange or the Nasdaq Stock Market, applicable SEC rules require us to determine whether Mr. Brimmer is also an independent director, as that term is defined by the listing standards of one of the foregoing stock markets. Mr. Brimmer is also an independent director, as that term is defined by Section 121(A) of the listing standards of the American Stock Exchange.

Compensation of Executive Officers

The following table sets forth, for the last three fiscal years, the compensation earned for services rendered in all capacities by our chief executive officer and the other highest-paid executive officers serving as such at the end of 2003 whose compensation for that fiscal year was in excess of \$100,000. The individuals named in the table will be hereinafter referred to as the Named Officers. No other executive officer of our company received compensation in excess of \$100,000 during fiscal year 2003. No executive officer who would otherwise have been included in this table on the basis of 2003 salary and bonus resigned or terminated employment during that year.

Summary Compensation Table

Name and Principal Position	Year	Annual Compensation			Long-Term Compensation Awards	
		Salary(\$)	Bonus(\$)	Other Annual Compensation (\$)	Securities Underlying Options (#)	All Other Compensation (\$)
Alan D. Roth (1)	2003	205,000	35,000	0	865,260	0
President, Chief Executive Officer & Chief Financial Officer	2002	0	0	0	0	0
	2001					

(1) Dr. Roth resigned from the Company in April 2004.

Options and Stock Appreciation Rights

The following table contains information concerning the grant of stock options under our 2003 Stock Option Plan and otherwise to the Named Officer during the 2003 fiscal year. No stock appreciation rights were granted during the 2003 fiscal year.

Option Grants in Last Fiscal Year (Individual Grants)

Name	Number of Securities Underlying Options Granted (#)	Percent of Total Options/SARs Granted to Employees in Fiscal Year ⁽²⁾	Exercise or Base Price (\$/Share)	Expiration Date
Dr. Roth	865,260 ⁽¹⁾	46%	1.49	6/25/2013

- (1) Option vests in three equal installments on February 18, 2004, February 18, 2005 and February 18, 2006, respectively.
- (2) Based on total option grants to employees of 1,264,760 in 2003. Options to purchase an additional 894,252 shares of common stock were granted to directors and consultants during 2003.

Option Exercise and Holdings

The following table provides information with respect to the Named Officer concerning the exercisability of options during the 2003 fiscal year and unexercisable options held as of the end of the 2003 fiscal year. No stock appreciation rights were exercised during the 2003 fiscal year, and no stock appreciation rights were outstanding at the end of that fiscal year.

Aggregated Option Exercises in Last Fiscal Year and Fiscal Year-End Option Values

Name	Shares Acquired on Exercise	Value Realized	Securities Underlying Unexercised Options at FY-End (#)		Value of Unexercised In-the-Money Options at FY-End (Market price of shares at FY-End less exercise price) ⁽¹⁾	
			Exercisable	Unexercisable	Exercisable	Unexercisable
Dr. Roth	0		0	865,260	\$0	\$95,179

- (1) Based on the fair market value of our common stock on December 31, 2003 of \$1.60 per share, the closing sales price per share on that date on the OTC Bulletin Board.

Long Term Incentive Plan Awards

No long term incentive plan awards were made to the Named Officer during the last fiscal year.

Compensation of Directors

Our directors receive no monetary fees for serving as directors. Non-employee directors may be granted, at the discretion of the Board, options to purchase shares of our common stock. Such options shall contain such terms and provisions as the Board determines at the time of grant. On October 28, 2003, in consideration for their services as directors, each of Drs. Aita, Stephen Roth and Weiser and Messrs. Brimmer, Rocamboli and Tanen received ten-year options to purchase 12,900 shares of our common stock at an exercise price of \$1.98 per share. All of these options vest in three equal installments on each anniversary of the grant date until fully vested. Members of the Board who are also employees or consultants of our company receive no options for their services as directors.

Employment Contracts and Termination of Employment and Change of Control Agreements

Alan D. Roth

Upon completion of the merger transaction between Surg II, Inc. and Chiral Quest, LLC on February 18, 2003, Alan D. Roth, Ph.D., was appointed our President, Chief Executive Officer and Chief Financial Officer. Dr. Alan Roth's employment with us was governed by the terms of an Employment Agreement dated November 5, 2002, which we assumed following the merger. The employment agreement was subsequently amended as of October 1, 2003. Dr. Roth's employment agreement provides for a term of 3 years at an annual salary of \$205,000 during the first year and \$240,000 thereafter. In addition, Dr. Roth was entitled to, and received, a bonus of \$35,000 following completion of the Surg II Chiral Quest, LLC merger. He was also entitled to an annual bonus of \$35,000, as well as an annual discretionary bonus, as the Board of Directors may determine. In October 2003, the employment agreement was amended to provide for additional bonus payments in the price of our common stock achieved certain price milestones, none of which were achieved. Pursuant to the terms of his employment agreement, Dr. Roth also received a ten-year option to purchase an aggregate of 865,260 shares of our common stock at an exercise price of \$1.49 per share.

Pursuant to a Separation Agreement dated effective as of April 2, 2004, Dr. Roth resigned from his positions as an officer and director of our company. Dr. Roth will continue to be employed by the Company until June 30, 2004, or such earlier date as Dr. Roth determines, in order to assist us in our transition to a new chief executive officer. During this transition period, Dr. Roth will continue to receive his annualized base salary of \$240,000. In connection with his separation, we have agreed to pay Dr. Roth a severance fee of \$375,000, less the amount of salary paid to him during the remaining period of his employment. Dr. Roth has also agreed to terminate all of his outstanding stock options, including the vested portions of such options.

Ronald Brandt

Following Dr. Roth's resignation, we appointed Ronald Brandt to be our interim Chief Executive Officer. Mr. Brandt will also continue to serve as our Vice President of Business Development. Mr. Brandt's employment with us is governed pursuant to a three-year employment agreement entered into in October 2003, pursuant to which he is entitled to an annual base salary of \$165,000. Mr. Brandt is also entitled to receive bonuses based on our gross revenues, as follows: (i) \$50,000 upon the completion of the first two consecutive fiscal quarters in which we have gross revenue in excess of \$500,000; (ii) \$100,000 upon the completion of the first two consecutive fiscal quarters in which we have gross revenue in excess of \$1,000,000; (iii) \$150,000 upon the completion of the first two consecutive fiscal quarters in which we have gross revenue in excess of \$2,500,000; (iv) \$10,000 for each fiscal quarter in which we have gross revenue in excess of \$2,500,000 following the first two consecutive fiscal quarters described in (iii) above; (v) \$250,000 upon the completion of the first two consecutive fiscal quarters in which we have gross revenue in excess of \$5,000,000; and (vi) \$10,000 (in addition to the \$10,000 described in (iv) above), for each fiscal quarter in which we have gross revenue in excess of \$5,000,000 following the first two consecutive fiscal quarters described in (v) above.

We also agreed to continue to pay to Mr. Brandt his base salary for 6 months, plus accrued bonuses, in the event we terminate his employment upon a change of control (as defined in the agreement) or for a reason other than for cause or as a result of a disability, provided, that our obligation to continue paying his base salary for a 6-month period will be reduced by the amount Mr. Brandt earns from other employment during that period.

In connection with his employment agreement, we also granted to Mr. Brandt an option to purchase 175,000 shares of our common stock at a price of \$1.67 per share, which vests in three equal annual installments beginning October 2004. Further, following his appointment as interim chief executive officer in April 2004, Mr. Brandt received an option to purchase an additional 25,000 shares at \$1.40 per share, which vests in 3 equal installments beginning April 2005.

PRINCIPAL SHAREHOLDERS

The following table sets forth certain information regarding beneficial ownership of the our common stock as of April 26, 2004, by (i) each person known by us to be the beneficial owner of more than 5 percent of the outstanding common stock, (ii) each director, (iii) each executive officer, and (iv) all executive officers and directors as a group. Unless otherwise indicated, the address of each of the following persons is 787 Seventh Avenue, 48th Floor, New York, New York 10019.

The number of shares beneficially owned is determined under rules promulgated by the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under those rules, beneficial ownership includes any shares as to which the individual has sole or shared voting power or investment power and also any shares which the individual has the right to acquire within 60 days of April 26, 2004, through the exercise or conversion of any stock option, convertible security, warrant or other right. Including those shares in the tables does not, however, constitute an admission that the named stockholder is a direct or indirect beneficial owner of those shares. Unless otherwise indicated, each person or entity named in the table has sole voting power and investment power (or shares that power with that person's spouse) with respect to all shares of capital stock listed as owned by that person or entity.

Name and Address	Number of Shares Beneficially Owned (1)	Percentage of Class
Ronald Brandt	2,000	*
Yaping Hong, Ph. D.	10,000(2)	*
Brian Lenz	0	*
Vincent M. Aita, Ph.D.	229,474	1.3
Kenneth W. Brimmer	150,000(3)	*
Stephen C. Rocamboli	107,669	*
Stephen A. Roth, Ph.D.	16,667(4)	*
David M. Tanen	107,699	*
Michael Weiser, M.D., Ph.D.	413,053	2.3
Xumu Zhang, Ph.D.	2,780,775	15.5
All Executive Officers and Directors as a group (8 persons)	4,889,304	20.9
J. Jay Lobell	2,179,818(5)	12.2
365 West End Avenue New York, NY 10024		

* Less than 1%.

- (1) Assumes in each case that the shareholder exercised all options available to the person that have vested or will vest within 60 days of March 26, 2004. Accordingly, this table does not reflect: (i) options to purchase 12,900 shares of common stock (at a price of \$1.91 per share) that have been granted to each of Dr. Aita, Mr. Brimmer, Mr. Rocamboli, Mr. Tanen, Dr. Weiser and Dr. Stephen Roth, all of which vest in 3 equal annual installments commencing October 28, 2004; (ii) 33,333 shares issuable upon exercise (at a price of \$1.50 per share) of an option granted to Dr. Stephen Roth, which shares vest in equal installments on February 14, 2005 and February 14, 2006; (iii) 487,539 shares issuable upon exercise of an option held by Dr. Zhang, 487,539 of which vest on three equal installments on each of May 15, 2005, May 15, 2006 and May 15, 2007; (iv) 15,000 shares issuable upon exercise (at a price of \$1.67 per share) of an option to Mr. Lenz, which vests in 3 equal annual installments commencing October 6, 2004, and 25,000 shares issuable upon exercise (at a price of \$1.40 per share) of an option to Mr. Lenz, which vests on 3 equal annual installments commencing April 19, 2005; (v) 175,000 shares issuable upon exercise (at a price of \$1.67 per share) of an option to Mr. Brandt, which vests in 3 equal annual installments commencing October 6, 2004, and 25,000 shares issuable upon exercise (at a price of \$1.40 per share) of an option to Mr. Brandt, which vests on 3 equal annual installments commencing April 19, 2005; and (vi) 40,000 shares issuable upon exercise (at a price of \$1.50 per share) of an unvested portion of an option granted to Dr. Hong, which will vest 11,000 shares on April 21, 2005, 12,000 shares on April 21, 2006 and 17,000 shares on April 21, 2007; and 50,000 shares issuable upon exercise (at a price of \$1.40 per share) of an option to Dr. Hong, which vests on 3 equal annual installments commencing April 19, 2005.
- (2) Includes 10,000 shares issuable upon exercise (at a price of \$1.50 per share) of a vested option.
- (3) Includes 7,500 shares which are owned by Mr. Brimmer's Individual Retirement Account, 2,500 shares which are owned by the Individual Retirement Account of Mr. Brimmer's spouse (to which he disclaims any beneficial interest), and 100,000 vested options.
- (4) Represents shares issuable upon exercise (at a price of \$1.70 per share) of an option, a portion of which vested February 14, 2004.
- (5) Based on Schedule 13G filed with the SEC on February 17, 2004. Includes 1,277,025 shares owned equally by five separate established trusts for the benefit of the children of Dr. Lindsay A. Rosenwald and 638,511 shares owned by three trusts established for the benefit of Dr. Rosenwald, which Mr. Lobell is the trustee/investment manager, and over which he has voting control and investment power.

CERTAIN TRANSACTIONS AND RELATIONSHIPS

Dr. Weiser and Messrs. Rocamboli and Tanen, all of whom are directors of our company, are employees of Paramount BioCapital, Inc. or its affiliates, a corporation of which Dr. Lindsay A. Rosenwald is the chairman and sole shareholder. Our treasurer, John Knox, is also an employee of Paramount. Dr. Rosenwald beneficially owns approximately 3.6 percent of our outstanding common stock and various trusts for the benefit of Dr. Rosenwald or members of his immediate family beneficially own approximately 10.7 percent of our outstanding common stock. Dr. Weiser and Messrs. Rocamboli, Tanen and Knox collectively own approximately 3.5 percent of our outstanding common stock. We currently pay \$4,000 per month to an affiliate of Paramount BioCapital for the use of office space in New York City, as well as for general and administrative services. Additionally, Paramount BioCapital participated as a placement agent in connection with our February 2004 private placement, for which it received aggregate commissions of approximately \$300,000.

MARKET FOR COMMON EQUITY AND RELATED SHAREHOLDER MATTERS**Market for Common Stock**

Since February 18, 2003, our common stock has traded on the on the OTC Bulletin Board under the symbol CQST.OB. From October 4, 2002, our common stock traded under the symbol SURG.OB and prior to that under the symbol SUGR.OB. The following table lists the high and low bid price for our common stock as quoted, in U.S. dollars, by the OTC Bulletin Board, as applicable, during each quarter within the last fiscal year. These quotations reflect inter-dealer prices, without retail mark-up, markdown, or commission and may not represent actual transactions. These quotations have been adjusted to reflect a 1-for-40 reverse split of our common stock effected October 4, 2002. Trading on our common stock has been sporadic, exemplified by the low trading volume and many days upon which no trades occurred.

<u>Quarter Ended</u>	<u>2004</u>		<u>2003</u>		<u>2002</u>	
	<u>High</u>	<u>Low</u>	<u>High</u>	<u>Low</u>	<u>High</u>	<u>Low</u>
March 31	\$2.48	\$1.50	\$ 1.65	\$ 1.62	\$ 12.00	\$ 1.60
June 30			2.50	1.55	8.80	2.80
September 30			2.23	2.00	4.80	2.00
December 31			1.83	1.50	4.00	0.65

Record Holders

The number of holders of record of our common stock as of March 22, 2004 was 1,717.

Dividends

We have not paid or declared any dividends on our common stock and we do not anticipate paying dividends on our common stock in the foreseeable future.

USE OF PROCEEDS

We will not receive any proceeds from the resale of any of the shares offered by this prospectus by the selling shareholders.

SELLING SHAREHOLDERS

The following table sets forth the number of shares of the common stock owned by the selling stockholders as of April 23, 2004, and after giving effect to this offering.

Name	Shares beneficially owned before offering	Number of outstanding shares offered by selling shareholder	Number of shares offered by selling shareholder issuable upon exercise of warrants	Percentage beneficial ownership after offering
Ross D. Ain	24,000	16,000	8,000	
Fred J. Allegrrezza	25,500	17,000	8,500	
Balanced Investment LLC	300,000	200,000	100,000	
Thomas J. Banholzer	10,500	7,000	3,500	
Bryan Becker	37,498	24,999	12,499	
David Becker	37,500	25,000	12,500	
Benjamin Partners Inc. Savings Plan FBO				
Jeffrey Benison	51,000	34,000	17,000	
Paul Bennett	15,000	10,000	5,000	
Alexander Bernt	12,000	8,000	4,000	
Stefanie Bernt	12,000	8,000	4,000	
David J. Bershad	90,000	60,000	30,000	
Daniel Bettencourt	15,000	10,000	5,000	
William H. Bland	6,000	4,000	2,000	
Rocco J. Brescia Jr.	75,000	50,000	25,000	
Brino Investment Ltd	49,999	33,333	16,666	
Benito Bucay	50,025	33,350	16,675	
William B. Buchanan, Jr.	49,999	33,333	16,666	
Richard & Grace Caldwell	6,000	4,000	2,000	
Keith D. Camp	15,000	10,000	5,000	
Devron H. and Valerie C. Char	22,500	15,000	7,500	
Elliot A. and Jean E. Cobb, JTWROS	30,000	20,000	10,000	
Roger & Margaret Coleman Jt Ten	49,999	33,333	16,666	
Concordia Partners L.P.	1,000,005	666,670	333,335	
Compact LLC	99,999	66,666	33,333	
Paul Michael Coplan	25,500	17,000	8,500	
George T. Corrigan Jr.	15,000	10,000	5,000	
David B. Cowles	25,500	17,000	8,500	
John Cowles	25,000	16,666	8,333	
Kevin T. Crofton	25,500	17,000	8,500	
Ronald Gerald Danielak	10,500	7,000	3,500	
Greg Dawe	57,000	38,000	19,000	
Andrew G. Denka	60,000	40,000	20,000	
Denno Family Ltd. Partnership	30,000	20,000	10,000	
Robert P. Deysher Living Trust	10,500	7,000	3,500	
Patrick R. Discepola	15,000	10,000	5,000	
Rene Dominguez	10,050	6,700	3,350	
Scott Doughman	10,500	7,000	3,500	

Edgar Filing: CHIRAL QUEST INC - Form 424B3

Name	Shares beneficially owned before offering	Number of outstanding shares offered by selling shareholder	Number of shares offered by selling shareholder issuable upon exercise of warrants	Percentage beneficial ownership after offering
E&M RP Trust	150,000	100,000	50,000	
Mark S. Eason	12,000	8,000	4,000	
Ellis Family Limited Partnership	60,000	40,000	20,000	
Enivia PTE Ltd.	99,999	66,666	33,333	
Luis Alfredo Farache	49,999	33,333	16,666	
Theodore H. Feller	10,500	7,000	3,500	
Peter Fink	15,000	10,000	5,000	
Christopher Fischler	6,000	4,000	2,000	
Thomas E. Fisk	15,000	10,000	5,000	
Marc Florin IRA	49,999	33,333	16,666	
Scott Frederichsen	15,000	10,000	5,000	
Dwight E. French	21,000	14,000	7,000	
Albert Fried, Jr.	150,000	100,000	50,000	
William J. Garner	10,050	6,700	3,350	
Alejandro Garza Garza	24,999	16,666	8,333	
Johan Magnusson Gedda	52,500	35,000	17,500	
Joel Good	15,000	10,000	5,000	
Peter Grabler	49,999	33,333	16,666	
Brett A. Granet	22,500	15,000	7,500	
Murray & Ujjaini Grigg	60,000	40,000	20,000	
Manish Gupta	6,000	4,000	2,000	
Curtis and Teresa Hagerty	15,000	10,000	5,000	
David Hallberg	6,000	4,000	2,000	
William M. and Deborah Haskell	6,000	4,000	2,000	
Steven Heggelke	10,500	7,000	3,500	
Gregory C. Herr	6,000	4,000	2,000	
Garry Higdem	75,000	50,000	25,000	
Gerald & Cynthia Hohman	10,500	7,000	3,500	
Larry D. Hunter	6,000	4,000	2,000	
John Igoe	22,500	15,000	7,500	
JR Construction Management Services, Inc.	24,999	16,666	8,333	
Richard A. Jacoby	49,999	33,333	16,666	
Patrick M. Kane	49,999	33,333	16,666	
Robert Kantor	74,998	49,999	24,999	
Brian Karasawa	15,000	10,000	5,000	
Keys Foundation	900,000	600,000	300,000	
Kevin P. Klett	6,000	4,000	2,000	
Brian Kugelman	10,500	7,000	3,500	
Jos. Kump & Joan Kump	51,000	34,000	17,000	
Michael D. Lachance	10,500	7,000	3,500	
Lisa Lanzarini	2,700	1,800	900	
Daniel E. Larson	30,000	20,000	10,000	
Gary W. Lefelar	10,500	7,000	3,500	
Ari Leman	10,500	7,000	3,500	
David D. Le Norman	25,500	17,000	8,500	
Michael Lusk	10,500	7,000	3,500	
Philip W. Madow	21,000	14,000	7,000	
George R. Martin	6,000	4,000	2,000	

Edgar Filing: CHIRAL QUEST INC - Form 424B3

Name	Shares beneficially owned before offering	Number of outstanding shares offered by selling shareholder	Number of shares offered by selling shareholder issuable upon exercise of warrants	Percentage beneficial ownership after offering
Eric D. Mathias	27,000	18,000	9,000	
A.J. Matyczynski	6,000	4,000	2,000	
MB Partnership	30,000	20,000	10,000	
Marc C. McGeever	6,000	4,000	2,000	
Brian E. & Mary S. McGovern	4,999	3,333	1,666	
Gary R. Meteer	10,500	7,000	3,500	
Gerald L. Meyr	15,000	10,000	5,000	
Arthur P. Mitchell	15,000	10,000	5,000	
Michael Mohr	30,000	20,000	10,000	
David Murcian	97,500	65,000	32,500	
Gregory Wayne & Judy Chumley Nelson	22,500	15,000	7,500	
Brent Olson	15,000	10,000	5,000	
John S. Osterweis, as ttee FBO The Osterweis Revocable Trust	49,999	33,333	16,666	
H. David Overbeeke	36,000	24,000	12,000	
Mario Pasquel & Begona Miranda	27,225	18,150	9,075	
Suman T. and Shobhana S. Patel	15,000	10,000	5,000	
Perkins Capital Management, Inc. Profit Sharing Plan U/A dtd 2/15/86	45,000	30,000	15,000	
Perkins Foundation	22,500	15,000	7,500	
Richard W. Perkins Trustee U/A dtd 6/14/78 FBO Richard W. Perkins	52,500	35,000	17,500	
Martin Jay Perl	6,000	4,000	2,000	
Josef Pickenhahn	15,000	10,000	5,000	
Porlana Capital Corp. PTE Ltd.	97,500	65,000	32,500	
Premero Investments Ltd.	14,971	9,981	4,990	
Pyramid Partners, L.P.	150,000	100,000	50,000	
UBS Financial Custodian for Rod J. Ragan	6,000	4,000	2,000	
Govin T. Rajan	24,000	16,000	8,000	
Elke R. de Ramirez	14,469	9,646	4,823	
Stephen A. Raymond	7,500	5,000	2,500	
Stephen A. Raymond, Trustee Pauline S. Johnson Trust U/A/D 2/10/86	10,500	7,000	3,500	
John P Ritchie and Marianne Ritchie JTWROS	7,500	5,000	2,500	
James W. Robertson	10,500	7,000	3,500	
Richard Rodick	6,300	4,200	2,100	
Joseph P. & Julie A. Rogers	19,500	13,000	6,500	
Harold Roitenberg, Trustee FBO Harold Roitenberg Trust U/A dtd 4/13/92	30,000	20,000	10,000	
John F. Rooney	37,500	25,000	12,500	
Alan D. Roth (1)	1,100,604(2)	80,000	40,000	4.8
Matthew J. Rund	6,000	4,000	2,000	
David J. Rupert	45,000	30,000	15,000	
David W. Ruttenberg	24,999	16,667	8,333	
Wayne Saker	60,000	40,000	20,000	
Russell B. Scaffede	18,750	12,500	6,250	
Michael H. Schwartz Profit Sharing Plan	49,999	33,333	16,666	
Francis P. Sears III	24,900	16,600	8,300	
Gabriel A. Segovia	40,500	27,000	13,500	

Edgar Filing: CHIRAL QUEST INC - Form 424B3

Name	Shares beneficially owned before offering	Number of outstanding shares offered by selling shareholder	Number of shares offered by selling shareholder issuable upon exercise of warrants	Percentage beneficial ownership after offering
Robert Segovia	27,570	18,380	9,190	
Joseph E. Simmons, Kathleen K. Casey JTWR0S	6,000	4,000	2,000	
Hargopal Singh	24,000	16,000	8,000	
Source One	100,500	67,000	33,500	
Spectra Capital Management, LLC	99,999	66,666	33,333	
Douglas W. & Audrey J. Stephens	15,000	10,000	5,000	
S. Michael Stinson	6,000	4,000	2,000	
Surucun Ltd	180,000	120,000	60,000	
Scott Swix	10,500	7,000	3,500	
Wayne F. Tackabury IRA	15,000	10,000	5,000	
Myron M. Teitelbaum MD	24,999	16,666	8,333	
Tisu Investment Ltd.	49,999	33,333	16,666	
Tokenhouse Trading S.P.	199,999	133,333	66,666	
Victor M. Tolomei	15,000	10,000	5,000	
Seckin Unlu	51,000	34,000	17,000	
Michael Unsworth	14,959	9,973	4,986	
Roger S. Vincent	25,500	17,000	8,500	
Richard L. Webb	9,000	6,000	3,000	
Thomas Webber	6,000	4,000	2,000	
David Weidner	6,000	4,000	2,000	
Melvyn J. Weiss	150,000	100,000	50,000	
Christopher J. Whyman IRA	24,900	16,600	8,300	
Gary L. Willoughby & Sarah R. Willoughby	21,000	14,000	7,000	
Tracie Winbigler	15,000	10,000	5,000	
ThinkEquity Partners LLC	73,680		73,680	
Richard Sands	60,000		60,000	
Wayde Walkr	15,000		15,000	
Kevin Wilson	7,500		7,500	
Richard Brewster	2,500		2,500	
Rafael Vasquez	2,500		2,500	
Matthew Eitner	2,500		2,500	
Matthew McGovern	40,185		40,185	
Nate Clay	1,500		1,500	
William Poon	1,800		1,800	
Joseph Faskowitz	1,500		1,500	
Richard Michalski	500		500	
Brian Smith	500		500	
James Ahern	500		500	
Scott Steele	200		200	
Anthony Miller	100		100	
Charles Savage	1500		1500	
David Bloom	100		100	
Matthew Donohue	100		100	
David Roth	750		750	
Tom Gaito	750		750	
Eli Pinchovsky	300		300	
Kent Mitchell	100		100	
Ian Rupert	200		200	
Lindsay A. Rosenwald	743,677		102,870	3.1

Edgar Filing: CHIRAL QUEST INC - Form 424B3

William Corcoran	4,228	4,228	
Scott Katzmann	64,811	64,811	
Bernard Gross	36,630	36,630	
Stephen C. Rocamboli (3)	107,699	5,000	*
David M. Tanen (4)	107,699	5,000	*
John Knox (5)	31,475	4,228	*
Basil Christakos	16,286	5,000	*
John Papadimitropoulos	27,175	4,228	*
Michael Rosenman	2,000	2,000	*
Benjamin Bernstein	3,000	3,000	*
Karl Ruggeberg	31,428	31,428	
Totals		4,826,906	2,896,135

* Denotes less than 1 percent.

- (1) Dr. Roth was our President, Chief Executive Officer and Chief Financial Officer, and a member of our board of directors until April 2004.
- (2) Includes 288,420 shares issuable upon the exercise of the vested portion of an option.
- (3) Mr. Rocamboli is our Interim Chairman of the Board of Directors.
- (4) Mr. Tanen is a director of our company.
- (5) Mr. Knox is our Treasurer.

PLAN OF DISTRIBUTION

We are registering the shares offered by this prospectus on behalf of the selling shareholders. The selling shareholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling shareholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

The selling shareholders may use any one or more of the following methods when disposing of shares or interests therein:

- ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
- block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
- purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
- an exchange distribution in accordance with the rules of the applicable exchange;
- privately negotiated transactions;
- short sales;
- through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
- broker-dealers may agree with the selling shareholders to sell a specified number of such shares at a stipulated price per share;
- a combination of any such methods of sale; and
- any other method permitted pursuant to applicable law.

The selling shareholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders under this prospectus. The selling shareholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

In connection with the sale of our common stock or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling shareholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling shareholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The aggregate proceeds to the selling shareholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling shareholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price of the warrants.

The selling shareholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act of 1933, provided that they meet the criteria and conform to the requirements of that rule.

The selling shareholders and any broker-dealers that act in connection with the sale of securities might be deemed to be underwriters within the meaning of Section 2(11) of the Securities Act, and any commissions received by such broker-dealers and any profit on the resale of the securities sold by them while acting as principals might be deemed to be underwriting discounts or commissions under the Securities Act.

To the extent required, the shares of our common stock to be sold, the names of the selling shareholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.

In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

We have advised the selling shareholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling shareholders and their affiliates. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling shareholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling shareholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.

We have agreed to indemnify the selling shareholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.

We have agreed with the selling shareholders to keep the registration statement that includes this prospectus effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement or (2) the date on which the shares may be sold pursuant to Rule 144(k) of the Securities Act.

Shares Eligible For Future Sale

Upon completion of this offering and assuming the issuance of all of the shares covered by this prospectus that are issuable upon the exercise or conversion of convertible securities, there will be 20,724,059 shares of our common stock issued and outstanding. The shares purchased in this offering will be freely tradable without registration or other restriction under the Securities Act, except for any shares purchased by an affiliate of our company (as defined in the Securities Act).

Our currently outstanding shares that were issued in reliance upon the private placement exemptions provided by the Securities Act are deemed restricted securities within the meaning of Rule 144. Restricted securities may not be sold unless they are registered under the Securities Act or are sold pursuant to an applicable exemption from registration, including an exemption under Rule 144 of the Securities Act. The 8,652,301 restricted shares of our common stock that were issued in connection with the February 2003 merger transaction between Surg II, Inc. and Chiral Quest, LLC became eligible for resale on February 18, 2004, subject to the satisfaction of the other requirements of Rule 144.

In general, under Rule 144 as currently in effect, any person (or persons whose shares are aggregated) including persons deemed to be affiliates, whose restricted securities have been fully paid for and held for at least one year from the later of the date of issuance by us or acquisition from an affiliate, may sell such securities in broker's transactions or directly to market makers, provided that the number of shares sold in any three month period may not exceed the greater of 1 percent of the then-outstanding shares of our common stock or the average weekly trading volume of our shares of common stock in the over-the-counter market during the four calendar weeks preceding the sale. Sales under Rule 144 are also subject to certain notice requirements and the availability of current public information about our company. After two years have elapsed from the later of the issuance of restricted securities by us or their acquisition from an affiliate, such securities may be sold without limitation by persons who are not affiliates under the rule.

Following the date of this prospectus, we cannot predict the effect, if any, that sales of our common stock or the availability of our common stock for sale will have on the market price prevailing from time to time. Nevertheless, sales by existing shareholders of substantial amounts of our common stock could adversely affect prevailing market prices for our stock.

DESCRIPTION OF CAPITAL STOCK

General

Our articles of incorporation, as amended to date, authorizes us to issue up to 50,000,000 shares of capital stock. Unless designated otherwise by our board of directors, all shares are designated as common stock. We have no shares of preferred stock authorized or outstanding. As of April 26, 2004, we had 17,827,924 shares of common stock issued and outstanding and no other shares of capital stock outstanding. The transfer agent and registrar for our common stock is Wells Fargo Bank Minnesota, N.A., St. Paul, Minnesota.

Common Stock

Holders of our common stock are entitled to one vote for each share on all matters to be voted on by our shareholders. Holders of our common stock do not have any cumulative voting rights. Common shareholders are entitled to share ratably in any dividends that may be declared from time to time on the common stock by our board of directors from funds legally available for dividends. Holders of common stock do not have any preemptive right to purchase shares of common stock. There are no conversion rights or sinking fund provisions for our common stock.

**DISCLOSURE OF COMMISSION POSITION ON
INDEMNIFICATION FOR SECURITIES ACT LIABILITIES**

Minnesota Statutes Section 302A.521 provides that a corporation shall indemnify any person made or threatened to be made a party to any proceeding by reason of the former or present official capacity of such person against judgments, penalties, fines, including, without limitation, excise taxes assessed against such person with respect to an employee benefit plan, settlements, and reasonable expenses, including attorney's fees and disbursements, incurred by such person in connection with the proceeding, if, with respect to the acts or omissions of such person complained of in the proceeding, such person has not been indemnified by another organization or employee benefit plan for the same expenses with respect to the same acts or omissions; acted in good faith; received no improper personal benefit and Section 302A.255, if applicable, has been satisfied; in the case of a criminal proceeding, had no reasonable cause to believe the conduct was unlawful; and in the case of acts or omissions by persons in their official capacity for the corporation, reasonably believed that the conduct was in the best interests of the corporation, or in the case of acts or omissions by persons in their capacity for other organizations, reasonably believed that the conduct was not opposed to the best interests of the corporation. Subdivision 4 of Section 302A.521 of the Minnesota Statutes provides that a corporation's articles of incorporation or by-laws may prohibit such indemnification or place limits upon the same. Our articles and by-laws do not include any such prohibition or limitation. As a result, we are bound by the indemnification provisions set forth in Section 302A.521 of the Minnesota Statutes. As permitted by Section 302A.251 of the Minnesota Statutes, the Articles of Incorporation of the Company provide that a director shall, to the fullest extent permitted by law, have no personal liability to us and our shareholders for breach of fiduciary duty as a director.

To the extent that indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. If a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of our company in the successful defense of any action, suit or proceeding) is asserted by any of our directors, officers or controlling persons in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of that issue.

ABOUT THIS PROSPECTUS

This prospectus is not an offer or solicitation in respect to these securities in any jurisdiction in which such offer or solicitation would be unlawful. This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission. The registration statement that contains this prospectus (including the exhibits to the registration statement) contains additional information about our company and the securities offered under this prospectus. That registration statement can be read at the SEC web site or at the SEC's offices mentioned under the heading "Where You Can Find More Information." We have not authorized anyone else to provide you with different information or additional information. You should not assume that the information in this prospectus, or any supplement or amendment to this prospectus, is accurate at any date other than the date indicated on the cover page of such documents.

WHERE YOU CAN FIND MORE INFORMATION

Federal securities law requires us to file information with the SEC concerning our business and operations. Accordingly, we file annual, quarterly, and special reports, proxy statements and other information with the SEC. You can inspect and copy this information at the Public Reference Facility maintained by the SEC at Judiciary Plaza, 450 5th Street, N.W., Room 1024, Washington, D.C. 20549. You can receive additional information about the operation of the SEC's Public Reference Facilities by calling the SEC at 1-800-SEC-0330. The SEC also maintains a web site at <http://www.sec.gov> that contains reports, proxy and information statements and other information regarding companies that, like us, file information electronically with the SEC.

VALIDITY OF COMMON STOCK

Legal matters in connection with the validity of the shares offered by this prospectus will be passed upon by Maslon Edelman Borman & Brand, LLP, Minneapolis, Minnesota.

EXPERTS

The consolidated financial statements of Chiral Quest, Inc. as of December 31, 2003, and for the year then ended, included in this prospectus, have been included herein in reliance on the report of J.H. Cohn LLP, independent public accountants, given on the authority of that firm as experts in accounting and auditing.

The consolidated financial statements of Chiral Quest, LLC as of and for the year ended December 31, 2002, included in this prospectus, have been included herein in reliance on the report, which includes an explanatory paragraph relating to the Company's ability to continue as a going concern, of Weinberg & Company, P.A., independent public accountants, given on the authority of that firm as experts in accounting and auditing.

CHANGES IN CERTIFYING ACCOUNTANT

Change from Weinberg & Company, P.A. to J.H. Cohn LLP

On December 9, 2003, we dismissed Weinberg & Company, P.A. as our independent public accountants. Our Audit Committee participated in and approved the decision to change independent public accountants. The report of Weinberg & Company, P.A. on our financial statements for the most recent fiscal year contained no adverse opinion or disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principle. In connection with its audit for the most recent fiscal year and through December 9, 2003, there had been no disagreements with Weinberg & Company, P.A. on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of Weinberg & Company, P.A. would have caused them to make reference thereto in its report on the financial statements for such years. During the most recent fiscal year and through December 9, 2003, none of the events specified in Item 304(a)(iv)(B) of Regulation S-B have occurred. Weinberg & Company, P.A. furnished us with a letter addressed to the SEC stating that it agrees with the above statements. A copy of such letter, dated December 30, 2003, was attached as Exhibit 16.1 to our Current Report on Form 8-K/A filed with the Commission on January 5, 2004.

On December 12, 2003, we retained J.H. Cohn LLP to be our principal independent public accountants. During the two most recent fiscal years and through December 12, 2003, we had not consulted with J.H. Cohn LLP regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on our financial statements, and either a written report was provided to us or oral advice was provided that J.H. Cohn LLP concluded was an important factor considered by us in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a disagreement and required to be reported under Item 304(a)(1)(iv) of Regulation S-B and the related instructions thereto.

Change from Virchow Krause & Co. LLP to Weinberg & Company, P.A.

Prior to the February 2003 merger transaction between Surg II, Inc. and Chiral Quest, LLC, the Surg II, our predecessor, had engaged Virchow Krause & Company as its independent public accountants. On April 21, 2003, following completion of the merger transaction, we dismissed Virchow, Krause & Company, LLP. Surg II's Board of Directors participated in and approved the decision to change public accountants. The report of Virchow, Krause & Company, LLP on the financial statements of Surg II, Inc. for the most recent fiscal year contained no adverse opinion or disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principle. In connection with its audit for the fiscal year ended December 31, 2002 and through April 21, 2003, there had been no disagreements with Virchow, Krause & Company, LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of Virchow, Krause & Company, LLP would have caused them to make reference thereto in its report on the financial statements for such year. During the fiscal year ended December 31, 2002 and through April 21, 2003, none of the events specified in Item 304(a)(iv)(B) of Regulation S-B occurred. Virchow, Krause & Company, LLP furnished us with a letter addressed to the SEC stating whether or not it agreed with the above statements. A copy of such letter, dated April 21, 2003, was attached as Exhibit 16.1 to our Current Report on Form 8-K filed with the SEC on April 25, 2003.

On April 21, 2003, we retained Weinberg & Company, P.A. to be our principal independent public accountants. Previous to the February 2003 merger transaction between Surg II, Inc. and Chiral Quest, LLC, Weinberg & Company, P.A. had been engaged as the independent public accounts of Chiral Quest, LLC. During the two fiscal years ended December 31, 2002 and through April 21, 2003, Chiral Quest, Inc., the successor to Surg II, Inc., had not consulted with Weinberg & Company, P.A. regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on Chiral Quest, Inc.'s financial statements, and either a written report was provided to Chiral Quest, Inc. or oral advice was provided that Weinberg & Company, P.A. concluded was an important factor considered by Chiral Quest, Inc. in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a disagreement and required to be reported under Item 304(a)(1)(iv) of Regulation S-B and the related instructions thereto.

Index to Consolidated Financial Statements

	Page
Report of J.H. Cohn LLP	F-2
Report of Weinberg & Company, P.A.	F-3
Consolidated Balance Sheets as of December 31, 2003 and 2002	F-4
Consolidated Statements of Operations for the Years Ended December 31, 2003 and 2002	F-5
Consolidated Statements of Changes in Stockholders Equity (Deficiency) for the Years Ended December 31, 2003 and 2002	F-6
Consolidated Statements of Cash Flows for the Years Ended December 31, 2003 and 2002	F-7
Notes to Consolidated Financial Statements	F-8 to F-20

F-1

Report of Independent Public Accountants

To the Board of Directors and Stockholders
Chiral Quest, Inc.

We have audited the accompanying consolidated balance sheet of Chiral Quest, Inc. and Subsidiary as of December 31, 2003, and the related consolidated statements of operations, changes in stockholders' equity (deficiency) and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Chiral Quest, Inc. and Subsidiary as of December 31, 2003, and their results of operations and cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

/s/ J.H. Cohn LLP

Roseland, New Jersey
February 6, 2004, except for Notes 10 and 11,
which are as of February 25, 2004

INDEPENDENT AUDITORS REPORT

To the Board of Directors of
Chiral Quest, LLC

We have audited the accompanying balance sheet of Chiral Quest, LLC (the Company), as of December 31, 2002 and the related statements of operation, changes in stockholders' deficiency and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above, present fairly, in all material respects, the financial position of Chiral Quest, LLC as of December 31, 2002, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

/s/ WEINBERG & COMPANY, P.A.

Boca Raton, Florida
March 15, 2003

CHIRAL QUEST, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2003 AND DECEMBER 31, 2002

	December 31, 2003	December 31, 2002
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 659,117	\$ 33,520
Accounts receivable, net of allowance for doubtful accounts of \$11,490 at December 31, 2003 and \$50,000 at December 31, 2002	51,705	12,456
Inventory	76,892	28,422
Prepaid expenses	50,052	-
Total Current Assets	837,766	74,398
PROPERTY AND EQUIPMENT, NET	254,649	67,011
SECURITY DEPOSITS	31,000	-
DEFERRED FINANCING COSTS	50,000	-
INTELLECTUAL PROPERTY RIGHTS, NET	412,442	318,320
TOTAL ASSETS	\$ 1,585,857	\$ 459,729
LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIENCY)		
CURRENT LIABILITIES		
Accounts payable	\$ 273,414	\$ 111,832
Accrued expenses	226,200	105,377
Due to related party	1,201	-
Notes payable	-	336,625
Deferred revenue, current portion	220,592	133,967
Total Current Liabilities	721,407	687,801
LONG-TERM LIABILITIES		
Deferred revenue, long-term portion	39,116	173,083
TOTAL LIABILITIES	760,523	860,884
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS EQUITY (DEFICIENCY)		
Common stock, \$.01 par value, 50,000,000 shares authorized, 13,001,018 shares issued and outstanding at December 31, 2003	130,010	-
Equity units, 11,500,000 units issued and outstanding at December 31, 2002	-	1,213,000
Additional paid-in capital	4,865,353	-
Additional members' equity	-	135,050
Deferred expenses	(758,824)	(356,400)
Accumulated deficit	(3,411,205)	(1,392,805)
Total Stockholders' Equity (Deficiency)	825,334	(401,155)

TOTAL LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIENCY)	\$ 1,585,857	\$ 459,729
---	--------------	------------

See accompanying notes to consolidated financial statements

F-4

CHIRAL QUEST, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 2003 AND 2002

	Year Ended December 31, 2003	Year Ended December 31, 2002	
	<u> </u>	<u> </u>	
REVENUE	\$ 669,036	\$ 191,613	
COST OF GOODS SOLD	196,045	6,763	
	<u> </u>	<u> </u>	
GROSS PROFIT	472,991	184,850	
	<u> </u>	<u> </u>	
OPERATING EXPENSES			
Management and consulting expenses	361,622	231,424	
Research and development	440,646	63,728	
Selling, general and administrative	1,012,182	193,449	
Compensation	601,780	197,596	
Depreciation and amortization	86,325	36,631	
	<u> </u>	<u> </u>	
Total Operating Expenses	2,502,555	722,828	
	<u> </u>	<u> </u>	
LOSS FROM OPERATIONS	(2,029,564)	(537,978)	
INTEREST EXPENSE	(2,809)	-	
INTEREST INCOME	13,973	-	
	<u> </u>	<u> </u>	
NET LOSS	\$ (2,018,400)	\$ (537,978)	
	<u> </u>	<u> </u>	
NET LOSS PER COMMON SHARE BASIC AND DILUTED	\$ (.16)		
	<u> </u>		
WEIGHTED AVERAGE SHARES OUTSTANDING BASIC AND DILUTED	12,476,789		
	<u> </u>		
PRO FORMA:			
NET LOSS PER COMMON SHARE BASIC AND DILUTED		\$ (.06)	
		<u> </u>	
WEIGHTED AVERAGE SHARES OUTSTANDING BASIC AND DILUTED		8,932,119	
		<u> </u>	

See accompanying notes to consolidated financial statements

**CHIRAL QUEST, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
FOR THE YEARS ENDED DECEMBER 31, 2003 AND 2002**

Equity Units
Units

Common Stock

Amount

Additional Members' Equity

Shares

Amount

Additional Paid-In Capital

Deferred Expenses

Accumulated Deficit

Total Equity (Deficiency)

)

Edgar Filing: CHIRAL QUEST INC - Form 424B3

Balance, January 1, 2002	10,750,000
\$	1,205,500
\$	135,050
	-
\$	-
\$	-
\$	(486,000)
)	
\$	(854,827)
)	
\$	(277)
)	
Exercise of unit options	750,000
	7,500
	-
	-
	-
	7,500
Amortization of deferred expenses	-

	-
	-
	-
	-
	129,600
	-
	129,600
Net loss	
	-
	-
	-
	-
	-
)	(537,978)
)	(537,978)
<hr/>	
<hr/>	
<hr/>	
<hr/>	
<hr/>	
<hr/>	
<hr/>	
<hr/>	
<hr/>	
Balance, December 31, 2002	
	11,500,000
	1,213,000
	135,050

Edgar Filing: CHIRAL QUEST INC - Form 424B3

)	(356,400)
)	(1,392,805)
)	(401,155)
) Conversion of Chiral Quest, LLC member units to Chiral Quest, Inc. common stock at 2/18/03 based upon a factor of .752374 (See Note 1 (B))	(11,500,000)
)	(1,213,000)
)	(135,050)
)	8,652,298
	86,523
	1,261,527
	-
Recapitalization of the Company (See Note 1(B))	
	4,348,720
	43,487
	2,964,211
	3,007,698
Options issued for services and rent	

Edgar Filing: CHIRAL QUEST INC - Form 424B3

) 639,615
(639,615

Amortization of deferred expenses

-

237,191

237,191

Net loss

) (2,018,400
) (2,018,400

Balance, December 31, 2003

			-
\$			-
\$			-
			13,001,018
\$			130,010
\$			4,865,353
\$			(758,824)
)			
\$			(3,411,205)
)			
\$			825,334

See accompanying notes to consolidated financial statements

CHIRAL QUEST, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2003 AND 2002

	2003	2002
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (2,018,400)	\$ (537,978)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	86,325	36,631
Amortization of deferred expenses	237,191	129,600
Changes in operating assets and liabilities:		
(Increase) decrease in accounts receivable	(39,249)	1,086
(Increase) decrease in other current assets	-	1,817
(Increase) decrease in inventory	(48,470)	(21,975)
(Increase) decrease in prepaid expenses	(50,052)	-
(Increase) decrease in security deposits	(31,000)	-
Increase (decrease) in accounts payable	161,582	(13,878)
Increase (decrease) in accrued expenses and due to related party	112,481	(20,961)
Increase (decrease) in deferred revenue	(47,342)	307,050
Net Cash Used In Operating Activities	(1,636,934)	(118,608)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from sale of equipment	-	8,684
Payments for purchased property, plant and equipment	(237,222)	(318)
Payments for intellectual property rights	(130,865)	(195,371)
Net Cash Used In Investing Activities	(368,087)	(187,005)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from notes payable	40,000	336,625
Payment of note payable	(376,625)	-
Payment of loan payable	-	(50,000)
Exercise of unit options	-	7,500
Cash received in merger and recapitalization	3,017,243	-
Payments for deferred financing costs	(50,000)	-
Net Cash Provided By Financing Activities	2,630,618	294,125
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	625,597	(11,488)
CASH AND CASH EQUIVALENTS BEGINNING OF YEAR	33,520	45,008
CASH AND CASH EQUIVALENTS - END OF YEAR	\$ 659,117	\$ 33,520

See accompanying notes to consolidated financial statements

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND NATURE OF OPERATIONS

(A) Nature of Operations and Liquidity

Chiral Quest, Inc. provides chiral products and services such as feasibility screening and process development work to the pharmaceutical and fine chemical industries. Chiral Quest, Inc. develops chemical catalysts used in the synthesis of desired isomers of chiral molecules using asymmetrical catalysis technology (the Technology) owned by the Pennsylvania State University Research Foundation (PSRF), the technology arm of The Pennsylvania State University (Penn State). Chiral Quest, Inc. has a worldwide, exclusive license from PSRF for the inventions covered by the license. The original license agreement was entered into on November 8, 2000 (See Note 5).

Since the Company's inception, it has generated sales revenue but not yet generated any net profits. Management believes that the Company's research and development (R&D) and manufacturing capacity will need to grow in order for the Company to be able to obtain significant licensing and manufacturing agreements with large fine chemical and pharmaceutical companies. Management believes that the Company's manufacturing capacity will be enhanced with its new office and laboratory space located in Monmouth Junction, New Jersey that was leased in June 2003.

Since inception the Company has incurred a cumulative deficit of \$3,411,205 through December 31, 2003. For the year ended December 31, 2003 the Company had a net loss of \$2,018,400. Management expects the Company's operating losses to increase significantly over the next several years, primarily due to expansion of its research and development programs, the hiring of additional chemists, and the expansion of its manufacturing capabilities. There can be no assurance that the Company will ever be able to operate profitably.

As of December 31, 2003, the Company had working capital of \$116,359 and cash and cash equivalents of \$659,117. If the Company is unable to significantly increase its revenues, it will most likely require additional financing by the end of the first quarter of 2005 in order to continue operations. The most likely sources of financing include private placements of the Company's equity or debt securities or bridge loans to the Company from third party lenders.

The Company's net cash used in operating activities for the year ended 2003 was \$1,636,934. The Company's net loss of \$2,018,400 was offset by an increase of accounts payable and accrued expenses of \$161,582 and \$112,481 respectively, along with amortization of approximately \$324,000.

The Company's net cash used in investing activities for the year ended 2003 was \$368,087. Investing activities expenditures consisted of purchases of property and equipment of \$237,222 and payments for intellectual property rights of \$130,865.

The Company's net cash provided by financing activities for the year ended 2003 was \$2,630,618. Financing activities included the repayment of a note payable to Paramount Capital LLC of \$376,625, along with cash received in the merger dated February 18, 2003 in the amount of \$3,017,243.

Edgar Filing: CHIRAL QUEST INC - Form 424B3

CHIRAL QUEST, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2003 AND 2002

Management anticipates that the Company's capital resources (See Note 11) will be adequate to fund its operations through December 31, 2004. However, changes may occur that would consume available capital resources before that time. The Company's combined capital requirements will depend on numerous factors, including: competing technological and market developments, changes in our existing collaborative relationships, the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights and the outcome of any potentially related litigation or other dispute, the purchase of additional capital equipment, acquisition of technologies, and the development and regulatory approval progress of its customers' product candidates into which the Company's technology will be incorporated.

Additional capital that may be needed by the Company in the future may not be available on reasonable terms, or at all. If adequate financing is not available, the Company may be required to terminate or significantly curtail its operations, or enter into arrangements with collaborative partners or others that may require the Company to relinquish rights to certain of its technologies, or potential markets that the Company would not otherwise relinquish.

The Company's ability to achieve profitability depends upon, among other things, its ability to discover and develop products (specifically new ligands), and to develop its products on a commercial scale through a cost effective and efficient process. To the extent that the Company is unable to produce, directly or indirectly, ligands in quantities required for commercial use, it will not realize any significant revenues from its technology. Moreover, there can be no assurance that it will ever achieve significant revenues or profitable operations from the sale of any of its products or technologies.

(B) Merger

On February 18, 2003, Chiral Quest, LLC merged (the Merger) with and into CQ Acquisition, Inc., a wholly owned subsidiary of Surg II, Inc. (Surg), a reporting public corporation with no current operations. Each member equity unit of Chiral Quest, LLC issued and outstanding on February 18, 2003 (Effective Date) was automatically converted into 0.752374 shares of Surg common stock. There were 4,348,720 shares of Surg common stock issued and outstanding and options to purchase an additional 682,875 shares immediately prior to the Effective Date. At the Effective Date, Chiral Quest, LLC had 11,500,000 member equity units outstanding. Accordingly, as a result of the Merger, Surg issued 8,652,298 shares of its common stock to the former members of Chiral Quest, LLC. In addition, immediately prior to the Effective Date, there were non-vested contingent options and warrants outstanding to purchase an aggregate of up to 1,210,000 of Chiral Quest LLC's member equity units, which following the Merger represented the right to purchase an aggregate of up to 910,374 shares of Surg common stock at \$1.49 per share. In connection with the Merger, Surg changed its name to Chiral Quest, Inc., formerly Chiral Quest, LLC (together with its subsidiary, the Company or Chiral Quest). Subsequent to the Merger on February 18, 2003, Chiral Quest, Inc., formerly Chiral Quest, LLC, reports its results of operations on a consolidated basis.

Generally accepted accounting principles in the United States of America require that the company whose equity holders retain a majority interest in a business combination, maintain the majority of board memberships and hold key management positions to be treated as the acquirer for accounting purposes. Since, following the Merger, the former members of Chiral Quest, LLC held approximately two-thirds of the outstanding common stock of the Company and these members comprise the majority of the Board of Directors along with holding key management positions, the

Edgar Filing: CHIRAL QUEST INC - Form 424B3

CHIRAL QUEST, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2003 AND 2002

Merger was accounted for as a reverse acquisition with Chiral Quest, LLC as the accounting acquiror (legal acquiree) and Surg as the accounting acquiree (legal acquiror).

If the Merger occurred between Surg II and Chiral Quest, Inc. as of January 1, 2002 pro forma results for revenues, net loss, and net loss per share would be as illustrated in the following table for the years ended December 31, 2003 and 2002:

	Pro Forma Year Ended December 31, 2003	Pro Forma Year Ended December 31, 2002
	<u> </u>	<u> </u>
REVENUES	\$ 669,036	\$ 256,991
	<u> </u>	<u> </u>
NET LOSS	\$ (2,074,531)	\$ (594,109)
	<u> </u>	<u> </u>
BASIC AND DILUTED LOSS PER COMMON SHARE	\$ (0.16)	\$ (0.05)
	<u> </u>	<u> </u>
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING - BASIC AND DILUTED	13,001,018	12,718,878
	<u> </u>	<u> </u>

The above pro forma financial information is not necessarily indicative of what the Company's results of operations would have been had the Merger occurred on January 1, 2002.

(C) Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Chiral Quest, Inc. and its subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.

(D) Cash and Cash Equivalents

The Company considers all highly-liquid investments with an original maturity of three months or less when acquired to be cash equivalents.

(E) Fair Value of Financial Instruments

The carrying value of financial instruments including cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the relatively short maturity of these instruments. The carrying value of the note payable approximates fair value based on the incremental borrowing rates currently available to the Company for financing with similar terms and maturities.

(F) Allowance for Doubtful Accounts

The Company establishes an allowance for uncollectible accounts receivable based on historical collection experience and management's evaluation of collectibility of outstanding accounts receivable.

CHIRAL QUEST, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2003 AND 2002

(G) Inventory

Inventory consists of raw materials, work in process and finished goods which are stated at the lower of cost (first-in, first-out) or market. Raw materials consist of chemical compounds. Work in process and finished goods, referred to as proprietary ligands, consist of material, direct labor and manufacturing overhead allocations.

(H) Property and Equipment

Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated methods are used. The estimated useful lives used for depreciation and amortization were three, five and seven years for leasehold improvements, laboratory/computer equipment and office equipment, respectively (See Note 3).

(I) Intellectual Property Rights

Intellectual property rights are being amortized over the lives of the underlying patents, which generally are seventeen years. Amortization expense recorded for the years ended December 31, 2003 and 2002 was \$36,792 and \$13,918, respectively. Amortization expense for each of the five years subsequent to the year ended December 31, 2003, is approximately \$25,000 per year.

(J) Revenue Recognition

Revenues are comprised principally of four main components: (1) the licensing of PSRF's Technology, (2) the sale of proprietary ligands, (3) feasibility screening, and (4) custom contract development. Revenues as they relate to the licensing of the Company's rights to PSRF's intellectual property are recognized over the applicable license periods. The Company assumes the financial risks related to these revenues by financing the research and development of PSRF's technology as well as the defense of PSRF's patents. Deferred revenue in the accompanying consolidated balance sheets represents amounts prepaid by customers to the Company for services to be performed and products to be delivered at a subsequent date. These deferred and unearned amounts will be recognized as revenue when earned. Revenues as they relate to the sale of manufactured proprietary ligands are recognized upon the shipping of the ligands to the customer. Revenues as they relate to feasibility screening are recognized upon the completion of project reports and investigational studies. Revenues as they relate to custom contract development are recognized upon the shipment of finished products. However, revenue is not recognized unless collectibility is reasonably assured.

(K) Income Taxes

From inception in October 2000 through September 30, 2002, the Company elected to be treated as a partnership for federal and state income tax purposes. As such, the Company did not pay income taxes, as any income or loss through September 30, 2002 was included in the tax returns of the individual members. Accordingly, no provision was made for income taxes in the accompanying consolidated financial statements through September 30, 2002.

CHIRAL QUEST, INC. AND SUBSIDIARY
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 DECEMBER 31, 2003 AND 2002

As of October 1, 2002, the Company elected to be treated as a C corporation for income tax purposes and has adopted SFAS No. 109 Accounting for Income Taxes. Under Statement 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under Statement 109, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when realization of deferred tax assets is not considered more likely than not.

If the Company were classified as a C corporation since inception, there would be no pro forma effect on income taxes because of the Company's recurring losses.

(L) Stock-Based Compensation

The Company accounts for its employee and director stock option plans using the intrinsic value method in accordance with APB Opinion No. 25, *Accounting For Stock Issued To Employees*, and related interpretations. The Company measures compensation expense for employee and director stock options as the aggregate difference between the market value of its common stock and exercise prices of the options on the date that both the number of shares the grantee is entitled to receive and the exercise prices are known. The Company values options issuances using the Black-Scholes option pricing model, with the following assumptions: risk-free interest rate of 2% to 4%, volatility of 70% to 130%, lives of 5 to 10 years, and an assumed dividend yield of 0%. If the Company had elected to recognize compensation cost for all outstanding options granted by the Company to employees by applying the fair value recognition provisions of SFAS No. 123 to stock-based employee compensation, net loss and loss per share would have been increased to the pro forma amounts indicated below:

	2003
Net loss as reported	\$ (2,018,400)
Total stock-based employee compensation expense using the fair value based method for all awards, net of related tax effects	(165,272)
Pro forma	\$ (2,183,672)
Basic and diluted net loss per common share:	
As reported	\$ (0.16)
Pro forma	\$ (0.18)

For the year ended December 31, 2002, there were no stock options issued or outstanding.

In addition, options are issued to non-employees such as consultants, scientific advisory board members and directors. Any options issued to non-employees are recorded in the consolidated financial statements in deferred expenses in the stockholders' equity section using the fair value method and then amortized to expense over the applicable service periods. See Note 6 for more discussion on the Company's stock-based compensation.

Edgar Filing: CHIRAL QUEST INC - Form 424B3

CHIRAL QUEST, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2003 AND 2002

(M) Use of Estimates

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

(N) Impairment of Long-Lived Assets

The Company evaluates the recoverability of its long-lived assets, where indicators of impairment are present, by reviewing current and projected profitability or undiscounted cash flows of such assets. Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Intangible assets not subject to amortization are tested for impairment at least annually. For the years ended December 31, 2003, and 2002, the Company determined that an impairment charge on its long-lived assets was not required.

(O) Research and Development Expense

R&D costs are expensed as incurred. These expenses include the cost of the Company's proprietary R&D efforts, as well as costs incurred in connection with the Company's third-party collaboration efforts.

(P) Advertising

The Company expenses the cost of advertising and promotions as incurred. Advertising costs charged to operations amount to \$174,514 and \$1,794 for the years ended December 31, 2003, and 2002, respectively.

(Q) Loss Per Share

Basic and diluted net loss per common share for all periods presented is computed based on the weighted average common shares outstanding during the year as required by Statement of Financial Accounting Standards No. 128, Earnings Per Share. The effects of potentially dilutive securities were not considered since the effect would be anti-dilutive.

Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share is the same as basic net loss per share, since potentially dilutive securities from stock options and stock warrants would have an antidilutive effect because the Company incurred a net loss during each period presented. The amount of potentially dilutive securities excluded from the calculation was 2,841,607 at December 31, 2003. There were no potentially dilutive securities at December 31, 2002.

Edgar Filing: CHIRAL QUEST INC - Form 424B3

CHIRAL QUEST, INC. AND SUBSIDIARY
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 DECEMBER 31, 2003 AND 2002

NOTE 2 INVENTORY

The principal components of inventory are as follows:

	December 31, 2003	December 31, 2002
Raw material compounds	\$ 25,796	\$ 28,422
Work in process	42,251	-
Finished goods	8,845	-
Total Inventory	\$ 76,892	\$ 28,422

NOTE 3 PROPERTY AND EQUIPMENT, NET

The cost of the major classes of property and equipment are as follows:

	December 31, 2003	December 31, 2002
Laboratory equipment	\$ 272,713	\$ 112,044
Office equipment	4,780	2,291
Computer equipment	26,131	-
Leasehold improvements	47,932	-
Totals	\$ 351,556	\$ 114,335

Depreciation and amortization expense for property and equipment for the years ended December 31, 2003 and 2002 was \$49,583 and \$22,713, respectively. Accumulated depreciation and amortization of property and equipment as of December 31, 2003 and 2002 was \$96,907 and \$47,324, respectively.

NOTE 4 INCOME TAXES

A deferred tax asset of approximately \$912,000 as of December 31, 2003, consisting primarily of the tax effect of net operating loss carryforwards of approximately \$-2-,280,000, has been fully offset by a valuation allowance because it is management's belief that realization of such amount is not considered more likely than not. Accordingly, the Company recognized no tax benefit for its pre-tax loss in 2003. The net operating loss carryforwards, if not used, will expire through 2023.

NOTE 5 RIGHTS TO INTELLECTUAL PROPERTY

The Company's exclusive right to certain PSRF patents are of material importance to the Company's success. These PSRF patents result from inventions by the Company's Chief Technology Officer (CTO), who is also an employee at Pennsylvania State University. The PSRF patents cover chemical formulations, processes for or intermediates useful in the manufacture of products and the uses of products. Protection for PSRF's individual products extends for varying periods in accordance with the date of grant and the legal life of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent and its scope of coverage. The Company is financially responsible for all aspects of these PSRF inventions, including legal and R&D expenses associated with the chemical developments. The Company is no longer obligated to license future inventions by the CTO to the Company.

CHIRAL QUEST, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2003 AND 2002

For the year ended 2003, the Company has not recognized any impairment charges to its patents, as management believes that the Company's patents have useful lives equivalent to its estimated amortization period of seventeen years.

NOTE 6 STOCKHOLDERS' EQUITY

In connection with two 5-year consulting agreements entered into by the Company in 2000, the Company issued 5,400,000 member equity units which converted into 4,062,820 shares of common stock. The deferred expense recorded in 2000 is being amortized over the terms of the agreements.

During 2002, the Company granted options to purchase 1,150,000 membership units or the equivalent of 865,230 shares of its common stock at a conversion rate of .752374 (see Note 1 (B)) to its CEO as required by his employment agreement with the Company. The options vest equally over a three-year period commencing with the date of the Merger (See Note 1), are exercisable at \$1.49 per share, the fair market value at the date of grant, and are for services to be rendered to the Company over the vesting period.

In connection with the Merger (see Note 1), the Company issued approximately 731,000 member equity units which converted into 550,000 share of common stock with an exercise price of \$1.25, to an independent consultant for services related to the Merger.

During May 2003, the Company issued options to purchase an aggregate of 20,000 shares of common stock to the landlord of new office space that the Company is leasing in New Jersey. The option issuance resulted in a charge to deferred expenses in stockholders' equity of \$9,845 for the value of the shares and is being amortized to rent expense over the term of the lease beginning in July 2003.

In June 2003, the Company issued options to purchase an aggregate of 740,052 shares of common stock at exercise prices ranging between \$1.49 and \$1.50 per share to two consultants (including 650,052 options issued to the CTO) and two members of the Company's Scientific Advisory Board. The total value of the option issuances of \$619,864 was valued using the Black-Scholes option pricing model with the following assumptions: a risk-free interest rate of approximately 2.4%, volatility of approximately 87%, lives of five years and an assumed dividend yield of 0%. The option issuances were charged to deferred expense in stockholders' equity and are being amortized to consulting expense over the applicable service periods.

In October 2003, a consultant for the Company received options to purchase 4,300 shares of common stock at an exercise price of \$1.96 per share. These options have fully vested on February 14, 2004. The total value of the option issuance resulted in a charge to deferred expenses in stockholders' equity of \$6,263 was valued using the Black-Scholes option pricing model with the following assumptions: a risk-free rate of 3%, volatility of 128%, estimated lives of three years and an assumed dividend yield of 0%.

Edgar Filing: CHIRAL QUEST INC - Form 424B3

CHIRAL QUEST, INC. AND SUBSIDIARY
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 DECEMBER 31, 2003 AND 2002

In November 2003, a consultant for the Company received options to purchase 2,500 shares of common stock at an exercise price of \$1.96 per share. These options will vest within six months of the date of grant. The total value of option issuance resulted in a charge to deferred expenses in stockholders' equity of \$3,643 was valued using the Black-Scholes option pricing model with the following assumptions: a risk-free rate of 3%, volatility of 128%, estimated lives of three years and an assumed dividend yield of 0%.

The following table is a breakdown of the total number of shares outstanding, shares issued to non-employees, directors, consultants, scientific advisory board members and options that have expired:

	2003	2002
Shares		
price		
	Weighted average exercise	
	Membership Units	
	Weighted Average Exercise Price	

Outstanding at

beginning of year

Edgar Filing: CHIRAL QUEST INC - Form 424B3

	998,105 ¹
\$	1.48
	-
	-
Granted	1,843,752
	1.47
	1,326,608
\$	1.48
Exercised	-
	-
	-
Cancelled	(250)
)	2.80
	-
	-
<hr/>	
<hr/>	
<hr/>	
Outstanding at end	

of year

2,841,607

\$

1.47

1,326,608

\$

1.48

Options exercisable

at year-end

1,114,755

-

Weighted-average

fair value of

options granted

during the year

\$

0.63

\$

1.48

¹The member equity units issued during the year ended December 31, 2002 have been converted to common shares as of the Merger date (See Note 1(B)) based upon a conversion factor of .752374 per membership unit.

Edgar Filing: CHIRAL QUEST INC - Form 424B3

CHIRAL QUEST, INC. AND SUBSIDIARY
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 DECEMBER 31, 2003 AND 2002

The following table summarizes the information about Plan stock options outstanding at December 31, 2003:

EXERCISE PRICE	NUMBER OUTSTANDING	REMAINING CONTRACTURAL LIFE (YEARS)	NUMBER OF OPTIONS EXERCISABLE
\$ 1.25	100,000	5.81	100,000
\$ 1.25	550,000	4.13	550,000
\$ 1.25	25,000	5.81	25,000
\$ 1.49	865,230	4.12	252,356
\$ 1.49	650,052	4.49	88,028
\$ 1.50	20,000	4.35	2,667
\$ 1.50	25,000	9.49	4,167
\$ 1.50	10,000	9.46	1,083
\$ 1.50	50,000	9.31	7,083
\$ 1.50	97,500	9.29	26,563
\$ 1.50	5,000	4.49	5,000
\$ 1.50	20,000	9.29	2,833
\$ 1.50	60,000	9.49	10,000
\$ 1.50	20,000	9.46	2,167
\$ 1.60	4,500	3.06	4,500
\$ 1.67	175,000	9.77	14,583
\$ 1.67	15,000	9.77	1,250
\$ 1.70	50,000	9.57	6,944
\$ 1.79	10,000	9.92	167
\$ 1.79	2,000	9.92	63
\$ 1.96	12,900	9.83	717
\$ 1.96	12,900	9.83	717
\$ 1.96	4,300	9.83	2,457
\$ 1.96	12,900	9.83	717
\$ 1.96	12,900	9.83	717
\$ 1.96	12,900	9.83	717
\$ 1.96	12,900	9.83	717
\$ 2.05	2,500	0.33	417
\$ 3.20	250	2.62	250
\$ 3.20	375	2.62	375
\$ 3.20	250	2.62	250
\$ 6.80	1,625	1.42	1,625
\$ 6.80	375	1.42	375
\$ 11.20	250	0.00	250
	2,841,607		1,114,755

NOTE 7 AGREEMENTS

Edgar Filing: CHIRAL QUEST INC - Form 424B3

Pursuant to a January 2002 agreement between the Company and a pharmaceutical product development customer, the Company granted the customer a worldwide, non-exclusive, royalty free license to certain of the Company's Intellectual Property Rights for research purposes only in connection with certain of the customer's compounds. The customer paid the Company a nonrefundable license fee of \$400,000 in 2002. The fee is being amortized to revenue through September 2005 when the agreement terminates. For the years ended December 31, 2003 and 2002, the Company has recognized income of \$114,241 and \$112,676, respectively, related to this agreement.

F-17

Edgar Filing: CHIRAL QUEST INC - Form 424B3

CHIRAL QUEST, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2003 AND 2002

In August 2002, the Company entered into a one-year scientific research agreement with another pharmaceutical product development customer to assist in the completion of a feasibility screening program and report. In consideration for the experimental activity, the customer paid a fee of \$30,000. The fee has been amortized to revenue through August 2003. For the years ended December 31, 2003 and 2002, the Company recognized income of \$19,726 and \$10,274, respectively.

In May 2003, the Company entered into a four-year consulting agreement with the CTO at an annual rate of \$120,000 per year. In addition, the CTO received an option to purchase 650,052 shares of common stock at \$1.49 per share as mentioned in Note 5.

In May 2003, the Company entered into an option agreement with the Science and Technology Bureau of Jiashan County in Zhejiang, Province of the People's Republic of China, China (Jiashan), whereby the Company has an option to acquire a laboratory facility in an industrial park near Shanghai. Jiashan is currently building 4,000 square meters of laboratory space to the Company's specifications. The Company will not pay rent for the initial 3 years of the lease, following which the Company, at its sole option, may rent the space for annual rent of no more than \$60,000. In addition, the Company will have the option to purchase the lab on commercially reasonable terms. Should the Company wish to occupy the laboratory after its estimated completion in the third quarter of 2004; it will begin to pay a maintenance fee of \$4,500 per month. For purposes of entering into the lease, the Company established a wholly owned subsidiary in Hong Kong, Chiral Quest Ltd., which in turn will be the sole shareholder of a subsidiary in the People's Republic of China (the China Sub). The Company intends to provide at least \$65,000 of capital to the China Sub by the end of the second quarter of 2004. In addition, the Company was also granted the option to purchase for \$750,000 approximately 33 acres of land adjacent to the industrial park where the lab will be established.

Pursuant to an October 2002 agreement with Penn State, the Company funded the services of four post-doctorate fellows who, under the supervision of the CTO, conducted research and provided research quantities of chiral ligands to the Company. The agreement expires on April 14, 2004. The approximate obligation payable by the Company through April 14, 2004 is approximately \$96,000. This amount consists principally of four post-doctorate salaries, fringe benefits, materials and supplies for the stated period.

NOTE 8 BUSINESS AND CREDIT CONCENTRATIONS

The Company had two customers which accounted for approximately 54% and 17%, respectively, of revenue for the year ended December 31, 2003. The Company had two customers who accounted for approximately 58% and 14%, respectively, of revenue for the year ended December 31, 2002.

The Company had two customers who accounted for approximately 52% and 39%, respectively, of net customer accounts receivable as of December 31, 2003. The Company had two customers who accounted for approximately 80% and 10%, respectively, of net accounts receivable as of December 31, 2002.

NOTE 9 COMMITMENTS AND CONTINGENCIES

Upon completion of the merger transaction between Surg II, Inc. and Chiral Quest, LLC on February 18, 2003, Alan D. Roth, Ph.D. was appointed President, Chief Executive Officer and Chief Financial Officer of the Company. Dr. Alan Roth's employment with the Company is governed by the terms of an Employment Agreement dated November 5, 2002, which the Company assumed following the merger. Dr. Roth's employment agreement was subsequently amended as of October 1, 2003. Dr. Roth's employment agreement provides for a term of 3 years at an annual salary of \$205,000 during the first year and \$240,000 thereafter. In addition, Dr. Roth was entitled to, and received, a bonus of \$35,000 following completion of the Surg II Chiral Quest, LLC merger and he is entitled to annual discretionary bonuses, as the Board of Directors may determine. In October 2003, the employment agreement was amended to provide for additional bonus payments, as follows: (i) \$3,500 upon such time as we execute a commercial contract providing for gross revenue to us in excess of \$50,000, which bonus has been paid to Dr. Roth; (ii) a one time bonus of approximately \$160,000 upon such time as the closing bid price of our common stock is at or above \$5.00 for five consecutive trading days; and (iii) a one time bonus of approximately \$160,000 upon such time as the closing bid price of our common stock is at or above \$8.00 for five consecutive trading days. If not already paid to Dr. Roth, the bonuses described in clauses (ii) and (iii) are payable in the event of a Change of Control (as defined in the agreement), provided that the per share price at which the change of control was effected was at or above the price milestones referenced in such clauses.

Edgar Filing: CHIRAL QUEST INC - Form 424B3

CHIRAL QUEST, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2003 AND 2002

Pursuant to the terms of his employment agreement, Dr. Roth also received a ten-year option to purchase an aggregate of 865,260 shares of the Company's common stock at an exercise price of \$1.49 per share. The options vest in three equal annual installments commencing February 18, 2004, and each anniversary thereafter until fully vested.

In the event Dr. Roth's employment with the Company is terminated for cause (as defined in the agreement), he is not entitled to any severance or other compensation beyond the date of such discharge. In the event Dr. Roth's employment is terminated as a result of a change of control (as defined in the agreement) in which the Company's shareholders receive aggregate consideration of at least \$50 million, then Dr. Roth is entitled to receive his base salary for a period of one year and all of his unvested options shall vest immediately and be exercisable for a period of 180 days thereafter.

In May 2003, the Company entered into an agreement to lease laboratory and office space located in Monmouth Junction, New Jersey. The lease commenced effective June 1, 2003 and is for a three-year term with a total rent, utilities and maintenance fees of approximately \$468,000 to be paid in monthly installments that increase each year. Due to the escalation clause in the lease, the Company is straight-lining the expense of the lease over the term of the lease. The Company also issued the landlord options to purchase 20,000 shares of common stock, as described in Note 6. The options issued to the landlord are amortized over the term of the option agreement and included in rent expense. The future minimum lease payments under this lease are as follows: \$136,730 for 2004, \$148,550 for 2005, and \$62,750 for 2006.

Total rent expense (which includes base rent, utilities, and operating escalations for both the New Jersey and Pennsylvania locations) for the Company for the year ended December 31, 2003 was approximately \$70,000. This amount reflects cost allocations to work in process, finished goods and cost of sales of approximately \$31,000.

The State College, Pennsylvania office maintains laboratory space for a yearly renewable lease at a monthly expense of approximately \$1,300. Total rent expense for the years ended December 31, 2003 and 2002 for the State College, Pennsylvania office was approximately \$15,000 each year.

Paramount BioCapital, LLC provides an office and general and administrative services in New York, New York for the Company's president and chief executive officer for an approximate monthly fee of \$4,000. This arrangement is renewable upon a yearly basis.

CHIRAL QUEST, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2003 AND 2002

In July 2002, the Company received a cease and desist letter from a competitor apprising the Company of the existence of a U.S. Patent. In October 2002, the Company and such competitor entered into a mutual confidentiality agreement in which each party agreed to exchange technology information in order to more fully evaluate whether either is infringing upon the rights of the other.

Also, in October 2002, the Company received an additional patent notification letter from another competitor apprising them of the existence of another U.S. Patent. To the Company's knowledge, no legal proceedings have been initiated with respect to any of the matters discussed in such letters.

NOTE 10 RELATED PARTY TRANSACTIONS

Paramount BioCapital Investments, LLC, a related party, has been performing certain administrative functions for the Company since July 12, 2002, and financed the Company through loans for working capital evidenced by a series of promissory notes (the Notes) aggregating \$376,625. The Notes bore interest at 5% and were repaid including interest in full on February 28, 2003, and subsequently cancelled.

Additionally, since September 1, 2002, the Company has been paying \$4,000 per month to Paramount BioCapital Investments, LLC, for administrative services. For the years ended December 31, 2003 and 2002, this resulted in charges to operations of \$48,000 and \$16,000, respectively. As of December 31, 2003, the Company owed \$1,201 to Paramount BioCapital Investments, LLC.

On February 25, 2004, the Company completed the sale of its securities in a private placement to accredited investors for gross proceeds of approximately \$7.2 million. Paramount BioCapital, Inc. participated as one of three placement agents for this transaction, for which it received approximately \$300,000 in commissions.

NOTE 11 SUBSEQUENT EVENTS

On February 25, 2004, the Company completed the sale of its securities in a private placement to accredited investors for gross proceeds of approximately \$7.2 million. Investors in the private placement purchased an aggregate of approximately 4.8 million shares of Chiral Quest's common stock at a price per share of \$1.50. Additionally, investors received 5-year warrants to purchase one share of common stock at \$1.65 per share for every two common shares purchased in the offering. ThinkEquity Partners LLC, Paramount BioCapital, Inc. and Casimir Capital L.P. acted as the placement agents for this offering and received fees of approximately \$500,000 of which Paramount BioCapital, Inc., a related party, received \$300,000. Net proceeds to the Company, after deducting commissions and other expenses relating to the private placement, were approximately \$6.7 million.

In February 2004, the Company amended the lease agreement in Monmouth Junction, NJ for additional laboratory space effective April 1, 2004. This additional laboratory space of 1,200 square footage increases rent expense for the year ending December 31, 2004 by approximately \$21,000, and annual rent expense thereafter of approximately \$28,000.

7,723,041 Shares

Common Stock

Chiral Quest, Inc.

PROSPECTUS

April 26, 2004

